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Abbreviations 
AD Alzheimer’s disease 
ADP Adenosine-di-phosphate 
ATP Adenosine-tri-phosphate 
ATP6 ATP synthase subunit 6 
BBB Blood brain barrier 
BCA Bovine calf serum 
BSA Bovine serum albumin 
cDNA Complementary DNA 
CNS Central nervous system 
COX Cytochrome c oxidase 
COX2 Cytochrome c oxidase subunit II  
COX IV Cytochrome c oxidase subunit IV 
Ct Threshold cycle 
CYTB Ubiquinol-cytochrome-c reductase complex cytochrome b 
subunit 
DEPC Diethyl pyrocarbonate 
DMEM Dulbecco’s modified Eagle’s medium 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
dNTP 2’-Deoxyribonucleoside-5’-tri-phosphate 
DTT Dithiotreitol 
ED Embryonic day 
EDTA Ethylenediamine tetraacetic acid 
E Estrogen 
FCS Fetal calf serum 
GABA γ-aminobutyric acid 
GAPDH Glyceraldehyde 3-phosphate dehydrogenase 
GD Gestation day 
GFAP Glial fibrillary acidic protein 
GLAST Glutamate aspartate transporter 
GLT-1 Glutamate transporter-1 
GPxs Glutathione peroxidase 
H2DCF-DA 2'7'-Dichlorodihydrofluorescein diacetate acetyl ester 
HD Huntington’s disease 
HEPES N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid 
HPRT Hypoxanthine guanine phosphoribosyl transferase 
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Htt Huntingtin 
Km Michaelis-Menten constant 
LDH Lactate dehydrogenase 
MEM Minimum essential medium 
MIM Mitochondrial inner membrane 
MnSOD Manganese superoxide dismutase 
MOM Mitochondrial outer membrane 
MPTP 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
MRC Mitochondrial respiratory chain 
MPP+ 1-Methyl-4-phenylpyridinium 
mtDNA Mitochondrial DNA 
MTT 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
NBM Neurobasal medium 
ND1 Mitochondrially encoded NADH dehydrogenase 1 
NeuN Neuronal N 
NPA 3-Nitropropionic acid 
NRF-1 Nuclear respiratory factor 1 
6-OHDA 6-Hydroxydopamine 
OPTI-MEM Optimal serum free minimum essential medium 
PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
PD Parkinson’s disease 
PGC-1α Peroxisome proliferator-activated receptor gamma coactivator 
1-alpha 
PI Propidium iodide 
Pink1 Serine/threonine-protein kinase, mitochondrial 
PLO Poly-L-ornithine 
PMSF Phenylmethylsulfonylfluoride 
RIPA buffer Radioimmunoprecipitation assay buffer 
RNA Ribonucleic acid 
RNS Reactive nitrogen species 
ROS Reactive oxygen species 
rpm Rotations per minute 
rRNA Ribosomal ribonucleic acid 
RT-PCR Real time-polymerase chain reaction 
SDS Sodium dodecyl sulphate 
siRNA Small-interfering ribonucleic acid 
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SNc Substantia nigra, pars compacta 
SSC Saline-sodium citrate 
TCA Tricarboxylic acid 
TH Tyrosine hydroxylase 
TN Turnover number 
TRAP1 Heat shock protein 75 kDa, mitochondrial 
Tris-HCl Tris-(hydroxymethyl) aminomethane-hydrogen chloride 
tRNA Transfer ribonucleic acid 
Vmax Maximal activity 
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2 General introduction 
2.1 Neural cells in the brain: neurons versus astrocytes 
2.1.1 Neurons 
The number of neurons in the brain shows a wide variation between species (Williams & 
Herrup, 1988) which affects thair range of computational skills. It is commonly believed that 
the human brain contains about 100 billion neurons, ten times more glial cells and 100 trillion 
synapses, but the absolute number of neurons and glial cells is unknown. Recent comparative 
studies challenge the common view that humans differ from other primates in their brain cyto-
architecture and indicate that equal numbers of neuronal and non-neuronal cells make the 
human brain an isometrically scaled-up primate brain (Azevedo et al., 2009).  
A neuron is an electrically excitable cell that processes and transmits information by 
electrochemical signaling along axons and between synapses. Neurons are the core 
component of the central nervous system (CNS) and peripheral nervous system (PNS). 
Classification of neuronal cells depend on their localization in the nervous system, their 
shape, polarity, direction of transmitted information, on the production of neurotransmitters, 
interactions with other neurons (excitatory, inhibitory or modulatory actions), and 
electrophysiological characteristics. The cell body of a neuron, the perikaryon, frequently 
bears to multiple dendrites but has never more than one axon, although the axon may branch 
hundreds of times before it terminates. Chemically connected neurons are following the major 
principle of synapses: signals are sent from the axon of one neuron to a dendrite of another. 
The axonal transport in both directions is essential for proper axonal and synaptic function 
because of the large distance that is separating synapses from neuronal cell bodies (Brown, 
2003; Morfini et al., 2006). In addition to membrane proteins and lipid components, whole 
organelles such as mitochondria can also be transported in an anterograde way along the axon 
to areas with a high metabolic demand. These areas are, for example, the growth cones, nodes 
of Ranvier, and synapses. For final degradation, mitochondria are transported in a retrograde 
way, from the axon to the cell body (Morris & Hollenbeck, 1993; Chevalier-Larsen & 
Holzbaur, 2006).  
Genetic and environmental factors may affect mitochondrial function in the neuronal cell 
bodies and processes, thereby disturbing neuronal metabolic homeostasis and leading to 
progressive degeneration of neurons.  
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In the past, brain function has been extensively studied, mainly focusing on the effects of 
toxic and degenerative processes on neuronal survival. Neurons are crucial for the chemical 
and electrical transmission of information between cells. Neuronal loss in certain brain areas 
characterizes several neurodegenerative disorders. However, during the past years, glial cells 
gained more and more importance for neuronal function and survival (Davies et al., 2006).  
2.1.2 Astrocytes 
In the CNS, glia cells are represented by three different cell types: 1) oligodendrocytes as 
myelin-forming cells that wrap layers of myelin membrane around axons to insulate them for 
impulse conduction; 2) microglia cells that are involved in inflammatory responses and 3) 
astrocytes which are closely associated with neurons and support their structure and function. 
Our view of astrocytes has grown considerably over the past decade. Astrocytes are 
interconnected through gap junctions, thus giving rise to what is called the ‘astrocytic 
syncytium’. It functions via induction of spreading waves of increased CA2+ in adjacent 
astrocytes (Dani et al., 1992; Koehler et al., 2006). The term ‘astrocyte’ refers to its star-like 
shape observed in histological (and cell culture) preparations, but the morphology of these 
cells varies widely and depends on the developmental stage of the organism, localization, and 
function in the brain. Two major forms of astrocytes exist in the CNS: protoplasmic and 
fibrous. The protoplasmic glia is found in grey matter tissue, possess a larger quantity of 
organelles, and exhibits short and highly branched cellular processes. The fibrous glia is 
usually located within white matter, has relatively few organelles, and exhibits long 
unbranched cellular processes. This type often has "vascular feet" that physically connect the 
cells to the outside of capillary wall. Thereby, these astrocytes take part in forming the blood- 
brain-barrier (BBB) (Deli & Joo, 1996; Risau et al., 1998; Davies et al., 2006) and are 
involved in transporting ions and other substances to sustain neurons and to regulate the 
extracellular environment (Fields & Stevens-Graham, 2002). Classically, astrocytes are 
known to be involved in regulating extracellular K+ levels necessary for maintaining neuronal 
excitability. Astrocytes are guiding neuronal processes and forming synapses via secreting 
many trophic factors (Chernausek 1993; Moretto et al., 1994; Rudge et al., 1994; Petrova et 
al., 2003). Although, astrocytes are electrically non-excitable cells, they express 
glutamatergic, GABAergic, purinergic, adrenergic, and serotonergic receptors and many 
others. They envelop synaptic junctions and possess transporters for the uptake of various 
neurotransmitters and modulators of the receptors. Thereby, they are exerting an influence on 
neuronal activity (Fellin & Carmignoto, 2004). The recycling of the primary excitatory 
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neurotransmitter glutamate can serve as an example. Glutamate is taken up from the 
extracellular space by glutamate transporters (GLT-1 and GLAST) and glutamine is returned 
back to neurons through the glutamate-glutamine shuttle (McKenna, 2007). Moreover, in 
response to disease or injury astrocytes turn into an activated status and migrate towards the 
affected area where they participate in repair and scarring processes (Fields & Stevens-
Graham, 2002).  
A very important function of astrocytes is to meet metabolic demands of neurons. 
According to the classical view of neuroenergetics, glucose crosses the BBB, is taken up in 
both neurons and glial cells via specific glucose transporters and is metabolized via glycolysis 
and the tricarboxylic acid (TCA) cycle to meet cell’s energy needs (Maher et al., 1994). 
Recent studies indicate that the energy production and consumption can be differentially 
distributed between neurons and astrocytes. Astrocytes are able to release the metabolic 
intermediate lactate which can be used by neurons (Pellerin & Magistretti, 2003; Pellerin & 
Magistretti, 2004). Moreover, astrocytes were shown to contain a glycogen reservoir which 
can be mobilized and used to enhance the lactate release (Dringen et al., 1993).  
In summary, under physiological conditions, astrocytes are important for retaining and 
supporting neuron functions and metabolism. Imbalanced metabolism plays a role in 
neurodegenerative diseases, such as Parkinson’s (PD) and Huntington’s (HD). In those 
disorders, mitochondrial pathology and an imbalanced energy production as well as oxidative 
stress are observed. Changes in mitochondrial function lead to an impairment of energy 
production in affected neuronal cells. This might be a signal for neighbouring astrocytes to 
mobilize additional sources of energy and, therefore, help to maintain the metabolic 
homeostasis of the brain.  
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2.2 The role of mitochondria in energy production and oxidative stress 
2.2.1 Mitochondria 
Mitochondria are organelles participating in life and death processes of the eukaryotic 
cells. They are involved in key metabolic reactions, produce most of the adenosine 
triphosphate (ATP), a source of chemical energy, and regulate a number of signaling cascades 
including apoptosis. According to endosymbiotic theory, mitochondria are originally derived 
from prokaryotes. Structurally, each mitochondrion has two membranes - the outer membrane 
(MOM) and the inner membrane (MIM) separated by the intermembrane space (Fig.1). The 
outer membrane is unfolded and encloses the entire organelle. The outer membrane is freely 
permeable to small molecules, such as ions and sugars. The MIM, where the machinery for 
mitochondrial respiratory chain (MRC) resides, has invaginations called cristae. Such an 
organization enlarges the surface area of the inner mitochondrial membrane, enhancing its 
ability to produce ATP. The inner compartment of the mitochondria, the matrix, is the space 
enclosed by the MIM. It is a concentrated aqueous solution of many enzymes and chemical 
intermediates involved in energy-yielding metabolism.  
 
 
 
 
Figure 1. Mitochondrial structure; described in text (adapted from www.umdf.org) 
 
 
Mitochondria have their own genetic material and the machinery to manufacture their own 
RNAs and proteins. Thus, mitochondrial matrix contains special mitochondrial ribosomes, 
tRNA, and several copies of the mitochondrial DNA genome, encoding 37 total genes: 
22 tRNA, 2 rRNA, and 13 peptide genes (Anderson et al. 1981). In mammals, the 13 
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mitochondrial peptides are integrated into the inner mitochondrial membrane along with 
proteins encoded by genes that reside in the host cell's nucleus. Mitochondria and the 
mitochondrial DNA are following the maternal inheritance in mammals.  
2.2.2 Mitochondrial respiratory chain: energy supply and oxidative stress 
Mitochondria play a critical role in cellular energy production via electron transport chain-
dependent production of ATP. MRC consist of five multimeric complexes: NADH-
ubiquinone-oxidoreductase (complex I; EC 1.6.5.3), succinate dehydrogenase (ubiquinone) 
(complex II; EC 1.3.5.1), ubiquinol—cytochrome-c reductase (complex III; EC 1.10.2.2), 
cytochrome c oxidase (complex IV; EC 1.9.3.1), and ATP synthase (complex V; EC 
3.6.3.14). Energy sources, such as glucose are initially metabolized in the cytoplasm. The 
products are imported into mitochondria, where they are catabolized using metabolic 
pathways including the TCA cycle, fatty acid oxidation, and amino acid oxidation. The end 
result of these pathways is the production of two kinds of energy-rich electron donors, NADH 
and succinate. Electrons from these donors are passed via redox reactions through an electron 
transport chain to oxygen, which is reduced to water. This electron transport is coupled to 
extrusion of protons through complexes I, III and IV into the intermembrane space creating a 
proton gradient across the inner mitochondrial membrane. Protons then flow back from inner 
membrane space to the matrix through ATP synthase, which use the energy to phosphorylate 
adenosine diphosphate (ADP) to ATP (Mitchell, 1961). Formation of ATP by this mechanism 
is known as oxidative phosphorylation (Fig. 2).  
In addition to the well-known role of the mitochondria in energy metabolism, regulation of 
cell death has recently emerged as a second major function of these organelles. One of the 
reasons of mitochondrial input in cell death is their role in generating intracellular reactive 
oxygen species (ROS), mainly during the oxidative energy metabolism (Fig. 3). Although 
several defence mechanisms to protect cellular macromolecules from demage have been 
developed during evolution, an excessive ROS production can lead to oxidation of 
macromolecules and has been implicated in mtDNA mutations, ageing, and cell death. ROS 
were found to randomly target proteins (Stadtman & Levine, 2000), lipids (Rubbo et al., 
1994), polysaccharides (Kaur & Halliwell, 1994) and DNA (Richter et al., 1988; LeDoux et 
al., 1999). The MRC as the major source of intracellular ROS generation is, at the same time, 
an important target for the damaging effects of ROS. The mitochondrial electron transport 
chain contains several redox centers that may leak electrons to molecular oxygen, serving as 
the primary source of superoxide production in most tissues. 
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Figure 2. Mitochondrial energy production 
The mitochondrial electron transport chain is composed of five multimeric complexes. Electron 
transport between complexes I to IV is coupled to extrusion of protons (H+) through complexes I, III 
and IV into the intermembrane space. H+ then flow through complex V (ATP synthase) which utilizes 
the energy to synthesize ATP from ADP and inorganic phosphate (Pi); c, cytochrome c; Q, ubiquinone 
(modified after http://biochemistryquestions.wordpress.com). 
 
 
There is growing evidence that most of the superoxide anions (O2•) generated by intact 
mammalian mitochondria in vitro are produced by complex I. This O2• production occurs 
primarily on the matrix side of the inner mitochondrial membrane (Cadenas et al., 1977; de 
Vries, 1986). O2• production by complex I was also found to be markedly stimulated in the 
presence of succinate, the substrate for complex II (Liu et al., 2002). In addition to complex I, 
complex III is regarded as an important site of O2• production (Grigolava et al., 1980; Turrens 
& Boveris, 1980). O2• produced at this site appears on both sides of MIM (Muller et al., 
2004). Ubiquinone, a component of the mitochondrial respiratory chain which links complex I 
with III and II with III, is considered as a major player in the formation of O2• by complex III 
(Turrens et al., 1985; Ott et al., 2007; Dröse & Brandt, 2008).  
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Figure 3. Mitochondrially produced reactive oxygen species. 
In the mitochondria, superoxide can be produced by respiratory complexes during the leakage 
electrons to oxygen. Complex I and complex III appear to be the main sources of mitochondrial 
superoxide production (O2•). ROS may reduce cytochrome c (c) or may be converted to hydrogen 
peroxide (H2O2) and oxygen. O2• is detoxified by manganese superoxide dismutase (MnSOD) to 
hydrogen peroxide. Glutathione peroxidases (GPxs) convert hydrogen peroxide to water. Reactive 
nitrogen species (RNS) can compete with MnSOD and form peroxynitrite (ONOO-). Peroxynitrite in 
turn initiates thiol oxidation or nitrosylation and tyrosine nitration. Increased steady state 
concentrations of O2_• may reduce transition metals which, in turn, react with H2O2 producing hydroxyl 
radicals (OH•). Both OH• and peroxynitrite are strong oxidants which indiscriminately react with 
nucleic acids lipids and proteins. Monoamine oxidase, localized in the outer membrane space produces 
H2O2 into the cytosol.; Q, ubiquinone (modified from Turrens, 2003 and Bayir & Kagan, 2008). 
 
 
The mitochondrial matrix has about 5- to 10-fold higher steady state concentration of O2• 
than the cytosol (Cadenas & Davies, 2000). This singles mitochondria to be a possible 
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primary target for the destructive effects of ROS. ROS may interact with mitochondrial 
macromolecules and, thus, impair the function of these organelles and directly influence cell 
viability and trigger cell death. Moreover, ROS generated by the complex I has been 
implicated in the pathogenesis of many disorders correlated with ageing. The notion that 
complex I defects are central to the development of sporadic PD originates from the 
observation that complex I inhibition induced by rotenone or 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) promotes PD-like symptoms and the formation of cytoplasmic 
inclusions of α-synuclein. In numerous studies the correlation between ROS and degenerative 
diseases, like PD, Alzheimer’s disease (AD) or HD has been reported (Barja & Herrero, 1998; 
Betarbet et al., 2002; Kushnareva et al., 2002; Nicholls, 2002; Sherer et al., 2003a, b; 
Trojanowski, 2003). 
 
2.3 Mitochondrial complex IV - a potential regulator in neurodegeneration  
Interactions of toxins like 3-nitropropionic acid (NPA) or 6-hydroxydopamine (6-OHDA) 
with MRC enzymes and consequences of these interactions on an impairment of 
mitochondrial function provide a great opportunity for understanding the role which 
mitochondria play in neurodegeneration. Despite the huge number of studies supporting, the 
idea that an impaired mitochondrial function drags cells directly into cell death, little is known 
about the regulatory and self-defense mechanism in mitochondria during pathology.  It is 
commonly known that decreased activity of complex IV is one of the main characteristics of 
AD, whereas inhibition of complex I and complex II was found to be specific in PD and HD, 
respectively. However, the relationship between the individual components of the MRC 
during neurodegeneration needs still to be explored. 
2.3.1 Mitochondrial complex IV - cytochrome c oxidase (COX) 
COX represents a terminal and rate-limiting enzyme complex located in the inner 
mitochondrial membrane. It catalyzes the transfer of four electrons from ferrocytochrome c 
via a CuA center (located in subunit II) to oxygen, which is bound at the binuclear center 
heme a3–CuB (located in subunit I) (Tsukihara et al., 1996). O2 is reduced to two H2O with 
four protons taken up from the matrix side. The reaction is coupled with the translocation of 
four protons from the matrix to the intermembrane space. 
 
     4 Fe2+-cytochrome c + 8 H+matrix + O2 → 4 Fe3+-cytochrome c + 2 H2O + 4 H+cytosol 
 18 
The reduction of O2 by COX occurs without formation of O2• or H2O2 due to its unique 
dioxygen binding structure which remained conserved during evolution from bacteria to 
mammals (Kadenbach, 2003; Yoshikawa et al., 2006). Structurally, mammalian COX is a 
dimeric enzyme where each monomer consists of three mitochondrial encoded catalytic (I–
III) and ten nuclear-encoded regulatory subunits (Grossman & Lomax, 1997). In 
Saccharomyces cerevisiae eleven subunits were found. In prokaryotes, however, three to four 
subunits were found in the enzyme (Bisson and Schiavo, 1986; Geier et al. 1995). The 
mammalian nuclear-encoded subunits occur in development-specific, tissue-specific, cell 
type-specific and stress condition-specific isoforms (Hütteman et al., 2001; Kadenbach et al., 
2004; Horvat et al., 2006; Singh et al., 2009). For example, different isoforms are expressed 
for subunits VIa, VIIa and VIII in heart and skeletal muscle and in non-muscle tissues. An 
isoform of subunit IV (IV-2) was identified in lung tissue (Huttemann et al., 2001), an 
isoform of subunit VIb (VIb-2) was found to be exclusively expressed in mammalian testes 
and a third isoform with unknown function was identified for subunit VIII (Lee et al., 2005).  
  
 
          
IV
ATP/ADP
 
Figure 4. The crystal structure of cytochrome c oxidase from bovine heart 
Each monomer of the dimeric enzyme contains three mitochondria-encoded subunits (I-III, green-
yellow backbone) containing the cytochrome c binding site and two copper atoms (CuA) in subunit II. 
Heme a and the oxygen binding site are located at the binuclear centre heme a3/CuB in subunit I. 
Subunit IV and the ATP/ADP binding site, is depicted in red (modified  from Kadenbach et al. 2000). 
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The expression of COX subunit IV isoforms is regulated by the oxygen concentration. This 
has been shown for yeast and mammals. In yeast, the homologous to mammalian COX 
subunit IV isoforms Va and Vb are present (Capaldi et al., 1986). Under normoxic conditions, 
COX isoform Va is expressed, whereas COX isoform Vb is transcribed at low oxygen 
concentration (below 0.5 M O2) (Burke et al., 1997; Kwast et al., 1998). The yeast COX 
complex comprising the isoform Vb displays an accelerated internal electron transfer step 
from heme a to heme a3 resulting in a higher turnover number (Allen et al., 1995). For the 
mammalian enzyme, a similar regulatory mechanism was described (Horvat et al., 2006). 
The biogenesis of COX represents a highly complex process involving more than 20 
assembly factors (Fernández-Vizarra et al., 2009). Recent data indicate that the nuclear 
respiration factor-1 (NRF-1) coordinates the expression of all 13 subunits. NRF-1 binds to the 
promotors of all ten nuclear-encoded subunits (Dhar et al., 2008), whereas the mitochondrial 
transcription factors A and B regulate the expression of the three mitochondria-encoded COX 
subunits. Although the nuclear-encoded subunits in the mammalian enzyme complex have 
been shown to enhance the catalytic efficiency of the enzyme, the precise role of many of 
these subunits remains unknown. 
2.3.2 Cytochrome c oxidase subunit IV (COX IV) and its isoforms  
There is a growing body of evidence that COX subunit IV, one of the regulatory subunits 
encoded by the nucleus, plays a crucial role in regulation of the enzyme by ATP. This 
regulation is mediated by localization and contact sites of subunit IV with the catalytic 
subunits I and II (Tsukihara et al., 1996). The catalytic activity of mammalian COX is 
regulated by binding of ATP to the N-terminus of subunit IV at the matrix side (Arnold and 
Kadenbach 1999). As described previously (Huttemann et al., 2001), COX subunit IV exists 
in two isoforms (IV-1 and IV-2). Both are transmembrane located proteins with the N-
terminus at the matrix side and the C-terminus at the intermembrane space. Despite the high 
homology of the two isoforms in the transmembrane region, there are large differences in 
nucleotide sequences of their terminal ends (Huttemann et al., 2001). COX isoform IV-1 is 
ubiquitously transcribed in all mammalian tissues, whereas isoform IV-2 shows high 
transcription levels in adult human and rat lung, human fetal lung and fetal muscle. In the 
brain tissue, a predominant expression of COX isoform IV-1 was detected but only marginal 
expression of COX isoform IV-2 mRNA was found in mouse cortical and striatal astrocytes 
(Horvat et al., 2006; Singh et al., 2009) In cerebellar granule cells, a higher amount of COX 
IV-2 was observed (Horvat et al., 2006). 
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The expression of COX subunit IV-1 isoform sensitizes the enzyme towards the cellular 
energy level and facilitates a link of the rate of ATP production to energetic demands. The 
underlying mechanism of this regulatory process involves the binding of ATP to subunit IV-1 
at high ATP/ADP ratio, thereby causing an allosteric inhibition of COX (Arnold & 
Kadenbach 1997; Arnold & Kadenbach 1999; Horvat et al., 2006). Under hypoxic or toxic 
conditions, mRNA expression of the isoforms switches to higher transcription levels of COX 
isoform IV-2. Appearance of COX IV-2 isoform in complex IV causes changes in the kinetics 
of COX and prevents the allosteric inhibition of COX by ATP, thereby suppressing the 
sensitivity of COX to high cellular energy levels (Horvat et al., 2006; Singh et al., 2009). 
Although the mechanisms leading to neurodegeneration are unknown, compelling evidence 
indicates that mitochondrial dysfunction occurs quite often in the several neurodegenerative 
disorders (Bowling & Beal, 1995; Beal, 1998; Trushina & McMurray 2007). Recently, Singh 
et al. (2009) described the involvement of COX isoform IV-2 in NPA mediated neurotoxicity 
through elevation of oxidative stress and necrotic cell death in striatal mouse astrocytes. With 
respect to a regulatory function of COX subunit IV, the different expression of the isoforms of 
this subunit challenges a possible role for COX regulation and consequently, for cell energy 
production and survival during neurodegeneration.  
 
2.4 Mitochondrial dysfunction in neurodegenerative disorders 
2.4.1 Neurodegeneration in general  
Neurodegeneration is a term describing cascade of events which leads to the progressive 
loss of structure and/or function of neurons including cell death. In addition to neuronal loss, 
astrocytes are impaired in their function and viability but may also be protective by 
astrogliosis formation (Fields & Stevens-Graham, 2002). On the other hand, many studies 
show the destructive role of astrocytes during neurodegenerative diseases by propagating the 
toxic effect to neurons (Satoia et al., 2005; Harris et al., 2004; Nagai et al., 2007). There is a 
growing body of evidence implicating that mitochondrial dysfunction seems to be one of the 
most important early events in neurodegenerative disorders like HD and PD because 
impairments in mitochondrial function mostly affect cells that have a high energy demand, 
such as neurons (Sieradzan & Mann, 2001; Pellerin & Magistretti, 2003; Mattson et al, 2008; 
Cicchetti et al., 2009). Moreover, many neurodegenerative diseases exhibit brain region-
specific pattern of neuronal loss (Dauer & Przedborski, 2003) which is often correlated to an 
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impairment of different mitochondrial function (Chaturvedi & Beal, 2008). Indicators of 
mitochondrial dysfunction observed in neurodegenerative diseases include ultrastructural 
changes, respiratory chain complex inhibition, decreased (or increased) ATP production, 
increased ROS production, mtDNA deletions, impaired Ca2+ buffering, loss of mitochondrial 
potential, imbalanced fusion fission processes and disturbed mitochondrial transport (Lin & 
Beal, 2006; Knott & Bossy-Wetzel, 2008; Chen & Chan 2009; Singh et al., 2009). 
Interestingly, in vivo and in vitro toxin-induced models of neurodegenerative disorders are 
based on impairment respiration through specific blockage of mitochondrial enzyme 
complexes of the respiratory chain.  
2.4.2 Mitochondrial dysfunction in Huntington’s disease 
HD is an autosomal dominant neurodegenerative disorder caused by expansion of a 
trinucleotide – (CAG) within huntingtin (Htt) resulting in polyglutamate repeats in the 
huntingtin protein (Brennan et al., 1985; Walker, 2007). At the cellular level, the early stage of 
HD is characterized by: 1) degeneration of medium spiny neuronal processes within the 
striatum, cerebral cortex and brainstem; 2) astrogliosis formation (Sieradzan & Mann, 2001; 
Mattson et al, 2008; Cicchetti et al., 2009). The late stage of HD is characterized by massive 
loss of neurons. Cell death occurs predominantly in the striatal GABAergic neurones and also 
the deep layers of the cerebral cortex (Ferrante et al., 1987; de la Monte et al., 1988; Martin & 
Gusella, 1986). Progressive neurodegeneration results in characteristic motor, 
cognitive/behavioral, and autonomic deficits, typically becoming noticeable in middle age. 
Little is known about the reasons why these particular brain regions are affected the most, as 
the mutated Htt was found to be ubiquitously expressed in all mammalian tissues (Sieradzan 
& Mann, 2001).  
Various studies suggest that the expression of mutant Htt is associated with mitochondrial 
dysfunction, thus causing bioenergetic defects and weight loss in HD patients despite caloric 
intake. Reduced glucose metabolism, decrease in N-acetylaspartate and increase in lactate in 
the basal ganglia was directly correlated with CAG repetitions (Feigin et al., 2001; Chaturvedi 
& Beal, 2008). Biochemical studies revealed decreased respiratory function of complex II and 
reduced activity of the TCA cycle, especially aconitase. NPA which is an irreversible 
inhibitor of succinate dehydrogenase (complex II), can cause HD like symptoms (Browne et 
al., 1997; Tabrizi et al., 1999; Brouillet et al., 2005). Disturbances in MRC can lead to ROS 
production, mtDNA depletions, impaired mitochondrial calcium buffering and decreased 
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mitochondrial membrane potential (Saulle et al., 2004; Beal, 2005; Seong et al., 2005; 
Brouillet et al., 2005; Panov et al., 2002).  
Evidence in support of a mitochondrial involvement in HD include destructive effects of 
mutant Htt on mitochondrial trafficking across the axons via interactions with proteins 
involved in mitochondrial transport (Chang et al., 2006). This could lead to reduced ATP 
level in synaptic terminals (Orr et al., 2008). Moreover, mutant Htt indirectly affects 
mitochondria by modifying gene transcription (Bae et al., 2005). The expression of several 
genes responsible for mitochondrial respiration and function (like PGC-1α, a coregulator with 
impact of energy homeostasis) is affected, when mutated Htt binds on transcription factors 
(Cui et al., 2006). Impairment of PGC-1α function may downregulate the defence system 
against ROS, resulting in increased oxidative damage and neuronal death.  
2.4.3 Mitochondrial dysfunction in Parkinson’s disease 
There is also good evidence supporting a major role for mitochondrial dysfunction in the 
pathophysiology of PD, the second most common age-associated, neurodegenerative disease 
in humans. PD is caused by a progressive loss of dopaminergic neurons in substantia nigra 
pars compacta (SNc). A loss of approximately 80% of synapses of nigral dopaminergic 
neurons and the subsequent lack of dopamine in the striatum causes PD symptoms including 
resting tremor, rigidity, bradykinesia and a characteristic unsteady gait (Dauer & Przedborski, 
2003). PD occurs more frequently in men than in women (Dluzen & McDermott, 2000). Most 
of the PD cases are sporadic and their etiology is unclear, although 10% of cases were found 
to be inherited. Part of the sporadic PD cases is induced by toxic agents, including MPTP or 
its toxic cation 1-methyl-4-phenylpyridinium (MPP+), paraquat, rotenone and 6-OHDA 
(Dauer & Przedborski, 2003). These toxins are used as animal and in vitro model of PD. 
Interestingly, they inhibit complex I of MRC. One of the major causes of neuronal cell death 
in PD is due to increased ROS and induced activation of caspases (Turmel et al., 2001; 
Schulz, 2006). In familiar PD, several genes involved in proper mitochondrial function, like 
Pink1 and Parkin, were identified. Pink1 is a serin/threonine kinase with an N-terminal 
mitochondrial targeting sequence localized in mitochondria and cytosol. Parkin is a cytosolic 
E3 ubiquitin ligase coordinating zinc ions (Dodson & Guo, 2007). Mitochondria from both 
knockouts exhibit mild defects in respiration and sensitivity to oxidative stress (Palacino et 
al., 2004; Gautier et al., 2008). Loss of Pink1 in human dopaminergic neurons or primary 
mouse neuronal cultures from mesencephalon and cortex can result in abnormal, swollen 
mitochondrial morphology and reduced viability (Wood-Kaczmar et al., 2008). Pink1 may 
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protect mitochondria against oxidative stress by phosphorylating the mitochondrial chaperone 
protein TRAP1 (Pridgeon et al., 2007). It is suggested that Pink1 may support mitochondrial 
function, whereas Parkin induces the elimination of dysfunctional mitochondria through 
mitophagy (Chen & Chan, 2009). Another characteristic of PD is the appearance of specific 
protein inclusions called Lewy bodies, in which the main component is the pathogenic form 
of α-synuclein. α-synuclein is located in presynaptic terminals and may be involved in 
dopaminergic signaling (Abeliovich et al., 2000). Mutations in α-synuclein lead to 
intracellular accumulations of this protein, decreased proteasome activity, increased levels of 
oxidative stress, and mitochondrial alterations and damage (Tanaka et al., 2001). Moreover, 
mutated α-synuclein can directly affect mitochondria by accumulating inside them or 
interacting with their outer membrane (Devi et al., 2008).    
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3 Scope of the study 
Several studies indicate that the neuron-glia interaction and metabolic coupling are crucial 
for proper brain function. Recently, neurosience research has focused on the involvement of 
neuronal and astrocytic mitochondria in the progression of neurodegenerative disorders. It is 
well-known that an impairment of mitochondrial functions, i.e. respiratory chain complexes, 
is involved in neurodegeneration. The main function of mitochondria is energy production 
which is accompanied by ROS generation. Selective inhibition of mitochondrial complex I of 
MRC mimics Parkinsonism, whereas inhibition of complex II induces HD-like symptoms in 
animal models. Little is known about the impact of complex IV –COX, the terminal and rate-
limiting enzyme of the respiratory chain. COX plays an important role in the regulation of 
energy metabolism and is a proper candidate for further investigation. In this study, I 
investigated the effect of mitochondrial toxins on COX subunit IV isoform expression and the 
consequences on mitochondrial function and neural cell survival.  
A major issue of the study was to determien whether astrocytes in vitro exhibit a brain 
region-specificity after toxification. Therefore, cultured primary astrocytes from different 
brain areas were treated with the mitochondrial toxin NPA, a model for HD. NPA impairs 
mitochondrial respiration by inhibition of complex II. I examined the effect of NPA on the 
expression of the regulatory COX subunit IV isoforms, the production of ATP and ROS, and 
astrocyte viability in the striatum compared to the cortex and mesencephalon. Furthermore, I 
aimed to unravel the functional importance of the elevated expression of COX isoform IV-2 
in primary striatal astrocytic cultures after NPA toxicity and its meaning for the increased 
vulnerability of striatal neural cells compared to other brain regions. By the use of a siRNA 
technique, I correlated mitochondrially produced oxidative stress and necrotic cell death with 
the up-regulation and decrease in expression of COX IV-2 and COX IV-1, respectively.  
Also, I studied the influence of 6-OHDA, an in vitro model for PD, on COX regulation. 
Knowing that PD occurs more often in men than in women, I aimed to demonstrate that 6-
OHDA affects the morphology and survival of primary mesencephalic neurons in a gender-
specific manner by influencing the transcription of mitochondrial genes, ATP and ROS 
production. 
This work was carried out in collaboration with Dr. Shilpee Singh from the Institute for 
Neuroanatomy of the RWTH Aachen University. In particular, the studies on isolated 
mitochondria were done in collaboration with Dr. Singh. 
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4 Material and methods 
4.1 Cell culture  
To study the influence of mitochondrial toxin NPA in astrocytes and 6-OHDA in neurons, 
primary astrocytes and neuronal cultures from mouse brains were prepared. BALB/c mice 
were purchased from Harlan Winkelmann GmbH (Borchen, Germany). All procedures were 
performed in strict accordance with the published Welfare rules for the care and use of 
laboratory animals at the University Clinic Aachen and the government of the State of 
Nordrhein-Westfalen, Germany. 
4.1.1 Primary astrocyte culture 
Primary striatal, cortical and mesencephalic astroglial cultures were prepared from 
postnatal day 1-3 BALB/c mice (Harlan Winkelmann GmBH, Germany) as previously 
documented (Arnold et al., 2008). Briefly, brains from decapitated mice were removed and 
transferred in preparation buffer consisting of 10 mM HEPES, 154 mM NaCl, 10 mM 
glucose, 2 mM KCl, and 15 µM BSA. Cerebral striatum, cortex and mesencephalon were 
dissected and after removal of meninges incubated in phosphate buffered saline (PBS) 
containing 0.1% (v/v) trypsin and 0.02% (w/v) EDTA for 15 min. Subsequently, the tissue 
was minced with a Pasteur pipette and filtered through a 50 µm nylon mesh. The cell 
suspension was centrifuged at 300 g (Eppendorf, Hamburg, Germany) for 5 min. The cells 
were re-suspended in Dulbecco’s modified Eagle’s medium (DMEM; PAA, Coelbe, 
Germany) supplemented with 16% (v/v) fetal calf serum (FCS; PAA, Coelbe, Germany), 50 
U/ml penicillin, 50 µg/ml streptomycin, 0.25 µg/ml amphotericin B (Fungizone®), 2 mM L-
glutamine (Glutamax®) and plated onto poly-L-ornithine (PLO) -coated (Sigma-Aldrich, 
Munich, Germany) culture dishes at a density of 1-2 x 106 cells per cm2. Astrocyte cultures 
were grown at 37°C in a humidified atmosphere of 95% air/5% CO2. Culture medium was 
replaced every third day. Before reaching confluence, cells were trypsinized and plated at 
lower density. Sub-confluent astrocytes were incubated in neurobasal medium (NBM) 
supplemented with 0.2% (v/v) B27, penicillin, streptomycin, Fungizone®, and L-glutamine 
for 48 h and subsequently used for experiments. The resulting final astroglia culture is 
characterized by > 95% homogeneity of GFAP-positive cells and no microglial or neuronal 
contamination (Pawlak & Beyer, 2005; Horvat et al., 2006). 
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4.1.2 Primary neuronal culture 
Primary neurons were prepared from mesencephali of Balb/c mouse brains at gestation day 
14/15 and cultured as described previously with some modifications (Schmidt et al., 1998). 
To distinguish between male and female fetuses the gonadal anlage was inspected. At this 
age, the testicular artery can be identified in a male fetus. The correctness of determining 
anatomically the gender of the fetuses was confirmed for the neuronal cell populations by 
qRT-PCR checking for female- (Xist) and male-specific (SRY) gene transcription. Briefly, 
mice embryos were taken from pregnant female mice after cervical dislocation. 
Mesencephalic tissues were taken and meninges removed. Subsequently, the tissue was 
mechanically dissociated and digested in the presence of 0.1% (v/v) trypsin and 0.02% (w/v) 
EDTA in PBS for 15 min at 37°C. The suspension was supplemented with 20% (v/v) heat-
inactivated FCS (PAA, Coelbe, Germany) and DNase I (170 U/ml; Sigma-Aldrich, Munich, 
Germany), triturated using a Pasteur pipette, and centrifuged for 5 min at 200 x g. Cells were 
resuspended in NBM supplemented with 0.4% (v/v) B27, 50 U/ml penicillin, 50 µg/ml 
streptomycin, 2 mM L-glutamine (Glutamax®), 10% (v/v) FCS and plated onto poly-L-
ornithine-coated (Sigma-Aldrich) culture dishes at a density of 1.5-2.0 x 105 cells per cm2. 
Cell cultures were maintained at 37°C in a humidified atmosphere of 95% air/5% CO2. After 
24 h, the cell medium was deprived of FCS. This procedure typically yields neuron-enriched 
cultures containing >90% neurons, of which ca. 2-3% were dopaminergic (TH-positive) cells, 
and <10% glial cells mostly astrocytes. 
4.1.3 Treatment of cell culture 
Astrocytes were used for experiments after the first replating and before reaching 
confluency. Before starting treatments, astrocytes were kept for 48 h under serum-free 
conditions with NBM (Invitrogen, Germany) supplemented with 1% glutamine, 0.2% B27 
(Invitrogen, Germany), (0.5%) penicillin/streptomycin, and (0.1%) fungizone for 48h. NPA 
was dissolved in NBM and further diluted to obtain final concentrations in cultures of 10 mM 
NPA for 48 h. This dose and time were found in previous experiments to be most effective in 
inducing COX subunit IV isoform 2 upregulation and its consequences in striatal astrocytes 
(Singh et al., 2009).  
Midbrain neuronal cells, cultivated 6 days in vitro, were treated for 24 h with fresh 
prepared 6-OHDA dissolved in NBM medium supplemented with 0.01% ascorbic acid to 
obtain the final concentration in cultures of 25 or 50 µM 6-OHDA. Concentrations and time 
frame for treatment were chosen from time and dose dependent experiments. To study a 
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possible recovery of the cells after treatment, neuron cultures were incubated for additional 48 
h post-toxin treatment in complete NBM medium under normal culturing conditions. 
Protective effects of 17β-estradiol (E; Sigma-Aldrich) at a concentration of 10-7 M were 
studied by pre-application for 3 h and/or co-application of E with 6-OHDA for 24 h. For 
comparison study, astrocytes from mesencephali were treated with 25, 50 or 250 µM 6-
OHDA in the same conditions. Additionally, to block the ATP production by glicolysis and 
mitochondrial oxidative phosforylation, 5 mM 2-deoxyglucose, 5 µg/ml oligomycin and 1 
mM cyanide were applied for 4 h.  
4.1.4 Small interfering RNA (siRNA) transfection  
Transfection of cultured astrocytes with siRNA (Ambion, Hundingdon, UK) was carried 
out after 48 h incubation in NBM when astrocytes reached the confluence of approximately 
85%. To achieve the knock-down of COX subunit IV- 1 and COX subunit IV- 2, siRNA 
against cox 4i1 and cox 4i2 were applied (Table 1.). siRNA transfection was optimized and 
the final concentration of 20nM oligonucleotides and 1,5 µl Lipofectamine RNAiMAX 
(Invitrogen, Karlsruhe, Germany) was applied. Reagents were diluted in serum-free 
OptiMEM I (Invitrogen, Karlsruhe, Germany), mixed and incubated for 20 min. 
Subsequently, siRNA-lipofectamine complex was implemented to astrocytes cultivated in 
antibiotics-free NBM. As a non-targeting siRNA control, silencer glycerinaldehyde-3-
phosphate dehydrogenase siRNA and siRNA negative control were used for transfection. 
(GAPDH siRNA; Negative Control #1, Ambion, UK) were used for transfection (data not 
shown). Transfection medium was changed to NBM with antibiotics after incubation for 24 h 
and cells were kept for additional 48 h in the presence or absence of 10 mM NPA. 
Transfection efficiency of astrocytes with siRNA against cox4i1 or cox4i2 of ca. 95% were 
reached. 
 
Table 1. siRNA used for transfection  
siRNA sequence 
gene 
accession 
number 
siRNA ID 
sicox4i1, 
siIV-1  5’-CCAAGCGAAUGCUGGACAUtt-3’ NM_009941 262859 
sicox4i2, 
siIV-2 5’-GCGAGUCUAUGUGUUCCCUtt-3’ NM_053091 175413 
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4.2 Biochemical methods 
4.2.1 Reverse Transcription 
Total RNA was isolated from treated and/or transfected cells and untreated controls using 
PeqGold RNA pure (PeqLab, Erlangen, Germany) according to manufacturer’s protocol. 
RNA concentration and purity were measured photometrically using BioPhotometer 
(Eppendorf). RNA integrity was tested randomly by 1% (w/v) agarose denaturing gel 
electrophoresis and ethidium bromide staining and visualized under UV-illumination. First 
strand complementary DNA (cDNA) was synthesized from 1 µg total RNA. In brief, total 
RNA dissolved in 11 µl diethyl pyrocarbonate- (DEPC-) H2O was pre-incubated at 70°C for 
5 min and placed immediately on ice. Subsequently, the reaction buffer consisting of 10 U/μl 
MMLV Reverse Transcriptase, 10 mM dithiotreitol, 50 mM Tris-HCl, pH 8.3, 75 mM KCl, 3 
mM MgCl2, 0.5 mM each dNTP (Roti-mix®PCR3, Roth, Karlsruhe, Germany), and 15 ng/µl 
random primers was added to RNA giving a final volume of 20 µl. After incubation for 40 
min at 55°C, reverse transcription was stopped by heat-inactivating the enzyme at 70°C for 20 
min. Addition of water instead of RNA served as negative control. 18S ribosomal RNA (18S 
rRNA) served for normalization of samples, whereas the housekeeping gene hypoxanthine 
guanine phosphoribosyl transferase (hprt), spanning over intron-exon borders, served as 
control for RNA purity. 
4.2.2 Real-time PCR analysis 
Gene transcription levels of COX subunit IV isoforms or mitochondrial encoded subunits 
were measured by real-time PCR (RT-PCR) using SYBR® Green technology and carried out 
on the iQ5 detection system (Bio-Rad, Munich, Germany). Forward and reverse primers for 
specific amplification of mitochondria-encoded subunits of the respiratory chain complexes 
and of nucleus-encoded complex IV subunit IV isoforms (Table 2.) were designed eliminating 
the possibility of amplifying genomic DNA (Araújo et al., 2008; Singh et al., 2009). Standard 
cDNA dilution series and sample cDNA obtained after reverse transcription and diluted 1:10 
were added to a solution containing 5 µM primers and IQ SYBR Green Supermix (Bio-Rad, 
Munich, Germany) consisting of 25 U/ml iTaq polymerase, 50 mM KCl, 20 mM Tris-HCl, 
0.2 mM each dNTP, 3 mM MgCl2, SYBR Green I and stabilizers. The RT-PCR reactions 
were conducted in standard 96-well plates and were composed of an initial denaturation step 
for 3 min at 95°C followed by 40 cycles consisting of 10 s at 95°C, 30 s at the appropriate for 
the target gene annealing temperature (Table 2.), 30 s at 72°C, and 10 s at 78°C. To obtain 
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melting curves for the resulting PCR products, a final step was added to the RT-PCR 
consisting of 81 cycles of increasing temperature from 55°C to 81°C by 0.5°C for 10 s each 
step. The PCR products were quantified using external standard dilution curves and the 
relative ΔCt method. Relative quantification relates the PCR signal of the target transcript to 
that of 18S rRNA in treated with respect to untreated cells. A test for an approximately equal 
efficiency of target amplification was performed by looking at ΔCt value variations with 
template dilutions. 18S rRNA and hprt served as endogenous control in the validation 
experiments. The absolute value of the slope of log input amounts versus ΔCt should be 
approximately -3.3 and the efficiency approximately 100%. The validation experiments 
passed this test. The results are expressed as an average of triplicate samples of at least three 
independent experiments for control and treated cells. 
 
Table 2. Primers used for polymerase chain reaction 
Target gene 
symbol 
Forward primer sequence  
Reverse primer sequence 
Annealing 
tempera-
ture  
Additional 
informations 
ND1 5’-TTTACGAGCCGTAGCCCAAA-3’ 5’-GGCCGGCTGCGTATTCTAC-3’ 53°C 
mitochondrial-
encoded 
cytB 5’-ACGAAAAACACACCCATTATTT-3’ 5’-CCGTTTGCGTGTATATATCGGATT-3’ 53°C 
mitochondrial-
encoded 
cox2 5’-AACCGAGTCGTTCTGCCAAT-3’ 5’-AACCCTGGTCGGTTTGATGTT-3’ 53°C 
mitochondrial-
encoded 
cox4i1 5’-TATGCTTTCCCCACTTACGC-3’ 5’-GCCCACAACTGTCTTCCATT-3’ 60°C 
nuclear-
encoded 
cox4i2 5’-AGATGAACCATCGCTCCAAC-3’ 5’-ATGGGGTTGCTCTTCATGTC-3’ 65°C 
nuclear-
encoded 
ATP6 5’-AGCAGTCCGGCTTACAGCTAA-3’ 5’-GGAGGGTGAATACGTAGGCTTG-3’ 53°C 
mitochondrial-
encoded 
18S rRNA 
5’-CGGCTACCACATCCAAGGAA-3’ 
5’-GCTGGAATTACCGCGGCT-3’ 
60°C housekeeping gene 
Hprt 
5’-GCTGGTGAAAAGGACCTC T-3’  
5’-CACAGGACTAGAACACCTGC -3’ 
61°C housekeeping gene 
 
4.2.3 SDS- PAGE and Western blot 
For immunoblotting, astrocytes or neurons were homogenized on ice in 
radioimmunoprecipitation assay (RIPA) buffer containing of 50 mM Tris-HCl (pH 7.4) 
hypotonic buffer with 1 mM EDTA, 1% Nonidet P-40 (Sigma, Igepal, CA), and protease 
inhibitor cocktail (Complete Mini, Protease inhibitor cocktail tablets, Roche, Mannheim, 
Germany). After centrifugation for 20 min at 13 000 g and 4°C, protein contents of the 
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extracts were measured with BCA Protein Assay Kit (Pierce, Rockford, IL, USA). Protein 
samples (30-50 µg per lane) were loaded onto and separated by 12.5% (v/v) discontinuous 
sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred 
onto a HybondTM – ECLTM nitrocellulose membrane (Amersham Biosciences, 
Buckinghamshire, UK) using Trans-Blot® SD Semi-Dry Electrophoretic Transfer Cell (Bio-
Rad). Protein transfer and equal loading of the samples was checked with Coomassie blue and 
Ponceau-S staining of the gels and the blots, respectively. The unspecific binding sites were 
blocked with 5 % non-fat milk (Carl Roth GmbH + Co.KG, Karlsruhe, Germany) in TBST 
buffer contains of 20 mM Tris, 0.15 M NaCl, 0.1% Tween20, pH 7.6. for 30 min. 
subsequently, nitrocellulose membrane was incubated for 24 h at 4°C with mouse monoclonal 
antibody against COX IV-1 (diluted 1:500; Mito-sciences, Eugene, Oregon, USA), mouse 
monoclonal antibody against COX IV-2 (diluted 1:500; Abnova, Heidelberg, Germany) and 
rabbit polyclonal antibody against β-actin (diluted 1:3000; Sigma, USA) in TBST buffer 
containing 5% (w/v) non-fat dry milk. Indirect immunodetection was performed with 
peroxidise-conjugated rabbit anti-mouse (1:3000, abcam, Cambrige, UK) or goat anti-rabbit 
IgG-HRP(1:3000, Sigma, USA)  secondary antibodies. Peroxidase activity was visualised 
using enhanced chemiluminescence ECLTM method according to standard protocol 
(Amersham Bioscience, Buckinghamshire, UK). For semi-quantitative evaluation of protein 
expression, immunoreactivity signals of protein bands were normalized to β-actin signals 
measured in the same blot. 
4.2.4 Protein determination 
The protein content of isolated mitochondria or cells was determined by applying the 
BCATM Protein Assay Kit (Pierce Bonn, Germany), according to manufacturer’s protocol. 
This method combines the reduction of Cu+2 to Cu+1 by protein in an alkaline medium (the 
biuret reaction) with the highly sensitive and selective colorimetric detection of the copper 
cation (Cu+1) using a unique reagent containing bicinchoninic acid. The purple-colored 
reaction product of this assay is formed by the chelation of two molecules of BCA with one 
copper ion. The water-soluble complex exhibits a strong absorbance at 562 nm that is nearly 
linear with increasing protein concentrations. Samples of frozen mitochondria in 
mitochondrial buffer and cells were solubilised in lysis buffer (for ATP assay) or RIPA buffer 
(for western blot), centrifuged at 12 000 g for 5 min at 4°C (Eppendorf 5417R), and the 
resulting supernatant was used for the protein assay. BSA served as standard in the range of 
4000 μg-25 μg. 
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4.2.5 Fluorescence immunocytochemistry 
Astroglial primary cultures or midbrain derived neurons in primary cultures cultivated on 
PLO-coated cover slips (Menzel, Braunschweig, Germany) were determined by 
immunocytochemistry. After removal of medium, cells were first stained in the presence of 1 
µg/ml Hoechst 33342 Trihydrochlorid (Hoechst; Invitrogen, Eugene, Oregon, USA) for 
15 min under culturing conditions. After washing with PBS (Gibco), the stained cells were 
fixed with 4% (w/v) paraformaldehyde (Merck) for 30 min at room temperature, washed 
twice with PBS, and permeabilized with PBS containing 0.2% (v/v) Triton X-100 (PBS-TX-
100, Merck) for 15 min. Blocking was performed in the presence of 3% (w/v) BSA (Carl 
Roth GmbH + Co. KG, Karlsruhe, Germany) in PBS for 20 min at room temperature.  
Primary antibodies were diluted in 3% (w/v) BSA in PBS and incubated with cells at 4°C 
overnight. Mouse monoclonal antibodies against Neu-N (MAB377, Chemicon, Temegula, 
CA), pan-neuronal (311) and –axonal (312) neurofilament markers (Convenance, California, 
USA) were used as a markers for neuronal cells and their processes. Rabbit polyclonal 
antibody against glial fibrillary acidic protein (anti-GFAP, Encor, Gainsville, FL, USA) was 
used as an astrocytes marker. To distinguish between dopaminergic cells among other 
neuronal cells the rabbit polyclonal anti-tyrosine hydroxylase (TH, Abcam, Cambrige, UK) 
antibody was applied. Finally, rabbit polyclonal antibody against active caspase 3 (abcam 
Cambrige, UK) was used to estimate the amount of caspase 3 induced apoptosis in 6-OHDA 
treated neuronal cultures.  
Subsequently, cells were washed three times with PBS and incubated in the presence of 
secondary antibodies diluted 1:500, for 2 h at room temperature. Anti-mouse IgG (H+L) 
secondary antibodies raised in donkey (Alexa Fluor® 488 labelled for green fluorescence) or 
goat (Alexa Fluor® 594 labelled for red fluorescence) were used for all mouse monoclonal 
primary antibodies.  Anti-rabbit IgG (H+L) secondary antibodies raised in goat (Alexa Fluor® 
488 labelled for green fluorescence) or donkey (Alexa Fluor® 594 labelled for red 
fluorescence) were used for rabbit polyclonal primary antibodies. Cells were washed with 
PBS three times for 5 min, sink in water and mounted with Mowiol (Fluka, Steinheim, 
Germany). Cells were examined using a fluorescence Axiophot microscope (Carl Zeiss, 
Oberkochern, Germany) equipped with the software NIS-elements AR 3.0 ® (Nikon, 
Düsseldorf, Germany) at excitation wavelengths of 365±12 nm (Hoechst), 450-490 nm (Alexa 
Fluor® 488) and 530-585 nm (Alexa Fluor® 594) or using a confocal LSM 7 DUO 
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microscope (Carl Zeiss) equipped with the software ZEN 2009 at the appropriate laser 
wavelength to excite the respective fluorophors.  
4.3 Functional assays on cells and mitochondria 
4.3.1 Intracellular ATP determination  
The intracellular ATP content of cultured astrocytes and neurons was determined using the 
ATP Bioluminescence Assay Kit HS II (Roche, Mannheim, Germany) according to the 
instructions of the manufacturer. Assay was based on the following principle. The luciferase 
from Photinus pyralis (American firefly) catalyses the following reaction:  
 
ATP + D-luciferin + O2 → oxyluciferin + PPi + AMP + CO2 + light 
The resulting green light has an emission maximum at 562 nm. 
 
In detail, transfected, treated and untreated cells were washed with ice-cold PBS re-
suspended in an equal amount of cell lysis reagent and dilution buffer.  After centrifugation 
for 10 min at 12 000 g at 4°C (Eppendorf 5417R, Hamburg, Germany), supernatants were 
transferred into a microtiter plate (Dynex, West Sussex, UK) and an equal amount of 
luciferase reagent was added. The luminescent reaction during absorbance/illumination at 562 
nm was analyzed immediately in a micro-plate reader (Victor, 1420 Multilabel Counter, 
Perkin Wallac GmbH, Freiburg, Germany). Subsequently, the protein content in the 
supernatant was measured by using BCA Protein Assay Kit (Pierce, Rockford, IL, USA) 
according to the manufacturer protocol. The ATP content of the transfected and/or treated 
cells was calculated and normalized to the amount of proteins with respect to untreated 
controls set as 100%.  
4.3.2 Intracellular reactive oxygen species detection 
Primary neurons were cultured in 96-well plates at a density of 5x104 cells/well. After 
treatment with or without 6-OHDA for 24 h, cells were loaded with 10 µM, 2′,7′-
dichlorodihydrofluorescein diacetate (2′,7′-dichlorofluorescin diacetate; H2DCFDA; 
Invitrogen) dissolved in DMSO, diluted in NBM medium and incubated for 45 min at 37°C. 
H2DCFDA is able to penetrate cells in its acetylated, non-fluorescent form. H2DCFDA is 
hydrolyzed by intracellular esterases to form 2',7'-dichlorofluorescin (DCFH). Oxidation of 
DCFH by hydrogen peroxide and hydroxyl radicals yields a highly fluorescent product, 2',7'-
dichlorofluorescein (DCF). The fluorescence intensity of DCF after excitation of the samples 
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at a wavelength of 485 nm was measured at an emission wavelength of 535 nm using a 
fluorescence microplate reader (Tecan GENios, Crailsheim, Germany). The fluorescence 
intensities were normalized to viability calculated from LDH release from death cells. 
4.3.3 Glycogen assay  
The glycogen content of astrocytes was determined using Glycogen Assay Kit (BioVision, 
Mountain View, CA, USA) accordingly to manufacturer’s instructions. In brief, NPA-treated 
and untreated control cells were homogenized with distilled water on ice and subsequently 
boiled for 5 min to inactivate enzymes. After centrifugation of boiled samples at 12 000 g for 
5 min to remove insoluble cell components, supernatants were taken and supplemented with 
Hydrolysis Enzyme Mix, Development Enzyme Mix, and OxiRed probe provided with the 
kit. The colorimetric measurement was performed in a microplate reader (Tecan GENios) by 
detecting the adsorbance at 570 nm. The glycogen content was calculated using glycogen 
standards with respect to controls (set as 100%). Determination of protein content was used 
for normalization. 
4.3.4 Preparation of mitochondria from primary astrocytes 
Mitochondria were prepared from primary astrocytes as described previously (Horvat et 
al., 2006). In brief, cells from culture dishes (about 3x107 astrocytes) were trypsinized and 
collected in mitochondrial buffer composed of 0.25 M sucrose, 10 mM Tris-HCl, 0.2 mM 
EDTA, 10 mM NaF, and 10 mM theophylline, pH 7.8. Cells were ruptured by applying a 
shock-freeze and thaw treatment. Digitonin (0.1 mg/ml) and triethanolamine at a final 
concentration of 10 mM were added to the cell suspension and incubated for 10 min on ice. 
Solubilized cells were homogenized in a pre-cooled glass vessel with a pestle (Eppendorf) 
rotating manually and subsequently centrifuged at 300 g for 10 min at 4°C (Eppendorf 5403). 
The resulting supernatant was transferred into a tube, while the pellet was re-suspended in 
mitochondrial buffer for another cycle of homogenization to optimize mitochondria isolation. 
Supernatants were pooled together and centrifuged at 12 000 g for 15 min at 4°C (Eppendorf 
5417). The final pellet containing mitochondria was re-suspended in mitochondrial buffer 
including 1 mM phenylmethansulfonyl fluoride to prevent proteolysis. Mitochondria were 
shock-frozen and aliquots were stored at -20°C until measurement. 
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4.3.5 Hydrogen peroxide detection in mitochondria  
Peroxide generation was measured using Amplex Red Hydrogen Peroxide/Peroxidase 
Assay Kit (Invitrogen). Freshly isolated mitochondria were re-suspended in minimal volume 
of mitochondrial buffer and added to 100 µl Krebs-Ringer phosphate buffer comprised of 145 
mM NaCl, 5.7 mM NaH2PO4, 4.86 mM KCl, 0.54 mM CaCl2, 1.22 mM MgSO4, 5.5 mM 
glucose, pH 7.35, containing 50 µM Amplex Red reagent and 0.1 U/ml horseradish 
peroxidase. Hydrogen peroxide in mitochondrial samples was detected by formation of 
resorufin, the fluorescent oxidation product of Amplex Red, using a fluorescence microplate 
reader (Tecan GENios, Crailsheim, Germany). The fluorescence of resorufin was excited at 
535 nm and its fluorescence emission detected at 595 nm. Application of distinct H2O2 
concentrations (0 – 3 µM) served as a standard to quantify sample H2O2 concentrations. 
Determination of protein in mitochondria was used for normalization. 
4.3.6 Polarographic measurements  
Mitochondria isolated from non-treated control and NPA-treated striatal astrocytes were 
thawed and kept on ice throughout polarographic measurements as suggested in Horvat et al., 
2006. To assess COX activity, mitochondria were re-suspended and solubilized in a buffer 
containing 50 mM KH2PO4, 1% (v/v) Tween® 80, pH 7.4 including 12 mM ascorbate, and 
either 5 mM ADP or 5 mM ATP, 1 mM phosphoenolpyruvate, 5 mM MgCl2 (Roth), and 5 
units pyruvate kinase at increasing concentrations (0-80 μM) of bovine heart cytochrome c 
(Fluka). The COX activity was measured using an Oxygraph system (Helmut Saur 
Laborbedarf, Reutlingen, Germany) and is given as turnover number (TN; consumed O2 [μM] 
/ (time [s] x total amount of protein [mg])). Maximal enzyme activity (vmax) was determined 
at 50 μM cytochrome c, and the Michaelis-Menten constant (Km) was calculated for COX 
kinetics in the presence of ADP or ATP including an ATP regenerating system using 
Lineweaver-Burk plots using the software Graphpad PRISM5. The Hill coefficient was 
calculated from the slope of plots of log v/(vmax – v) against log cytochrome c concentration 
([μM]). 
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4.4 Cell viability assays 
4.4.1 Apoptosis and necrosis assays 
To distinguish between apoptotic and necrotic astrocytes, transfected NPA-treated and 
untreated cells were cultured on poly-L-ornithine-coated cover slips (Menzel, Braunschweig, 
Germany) and stained with Hoechst-YO-PRO-1-propidium iodide method as described 
previously (Singh at al., 2009). Briefly, the cells were stained with 3 µM YO-PRO-1 
(Invitrogen, Karlsruhe, Germany) for 30 min followed by addition of 2 µg/ml Hoechst 
(10 min.). After the staining procedure, cells were washed twice with PBS, fixed with 100% 
ice-cold methanol (Merck) for 10 min at -20°C and washed with PBS. Subsequently, cells 
were incubated in 2x SSC buffer consisting of 0.3 M NaCl, 0.03 M sodium citrate, pH 7.0, for 
20 min and treated with 1 µM propidium iodide (Invitrogen) in 2x SSC buffer for 5 min 
followed by a washing step with PBS and mounting. Viable, apoptotic (Hoechst- and YO-
PRO-1 positive), and necrotic (Hoechst-, YO-PRO-1-, and propidium iodide-positive) cell 
nuclei were scored under a fluorescence Axiophot microscope (Carl Zeiss, Oberkochern, 
Germany) at excitation wavelength of 365 nm (Hoechst), 485 nm (YO-PRO-1), and 530 nm 
(propidium iodide). Cell nuclei of three independent experiments were counted in three 
distinct and randomly selected areas (3x105 µm2 per field) per cover slip using the NIS-
elements AR 3.0 ® software (Nikon, Düsseldorf, Germany).  
To distinguish between apoptotic and necrotic neurons, 6-OHDA-treated and untreated 
control cells were cultured on poly-L-ornithine coated coverlips and stained with a 
combination of Hoechst 33342, propidium iodide and active caspase 3. Cells were first 
incubated in the presence of 1 µg/ml Hoechst 33342 trihydrochloride (Hoechst; Invitrogen) 
for 15 min under culturing conditions and subsequently washed twice with PBS. Thereafter, 
cells were incubated in 2x SSC buffer consisting of 0.3 M NaCl, 0.03 M sodium citrate, pH 
7.0 for 10 min and treated with 1 µM propidium iodide (PI; Invitrogen) in 2x SSC buffer for 
10 min followed by a washing step with PBS. Subsequently, cells were fixed with 4% (w/v) 
paraformaldehyde (Merck) for 30 min at room temperature, washed twice with PBS, and 
permeabilized with PBS containing 0.2% (v/v) Triton X-100 for 15 min. Blocking was 
performed in the presence of 3% (w/v) BSA in PBS for 20 min at room temperature. Primary 
polyclonal antibody against active caspase 3 (Abcam) diluted in 3% (w/v) BSA in PBS was 
incubated with the cells at 4°C overnight. Cells were washed three times with PBS and 
incubated in the presence of the secondary goat anti-rabbit Alexa Fluor® 488-conjugated 
antibody (Invitrogen) for 2 h at room temperature. After washing, cells were mounted with 
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Mowiol. Viable, apoptotic (Hoechst- and active caspase 3-positive), and necrotic (Hoechst- 
and PI-positive) cell nuclei were scored under a fluorescence Axiophot microscope (Carl 
Zeiss) at excitation wavelength ranges of 365±12 nm (Hoechst), 450-490 nm (Alexa Fluor® 
488), and 530-585 nm (PI). Cell nuclei of three independent experiments were counted in 
three distinct and randomly selected areas (3x105 µm2 per field) per cover slip using the NIS-
elements AR 3.0 ® software. Data are presented as percentage of control set 100%. 
4.4.2 Measurement of lactate dehydrogenase (LDH) activity by LDH assay 
In order to estimate cell death, the level of LDH released from damaged cells into culture 
media was measured after treatment. A colorimetric assay was applied. According to the 
principal, the amount of formazan salt formed after conversion of lactate to pyruvate followed 
by reduction of tetrazolium salt is proportional to LDH activity in the sample. Medium from 
cultured cells was collected from each well and incubated with the appropriate reagent 
mixture according to the manufacture protocol (Cytotoxicity Detection Kit, Roche, 
Mannheim, Germany) at RT for 30 min. The red colour formed during incubation was 
measured at a wavelength of 490 nm. The intensity was proportional to LDH activity and to 
the percentage of damaged cells. Data were normalized to the activity of LDH released from 
Triton X-100 treated cells (100% of cell death) and expressed as a percentage of death cells. 
Controls were set as 100%. 
4.4.3 CellTiter-Blue® Cell Viability Assay 
For estimating the number of viable cells after 6-OHDA treatment or 6-OHDA treatment 
followed by 48 h recovery period in complete NBM medium, primary neuronal cells were 
cultured in 96 well-plates and assayed by the CellTiter-Blue® Cell Viability Assay (Promega, 
Germany), a homogeneous, colorimetric method. It uses the indicator dye resazurin to 
measure the metabolic capacity of cells - an indicator of cell viability. Viable cells retain the 
ability to reduce resazurin into resorufin. The spectral properties of CellTiter-Blue® Reagent 
change upon reduction of resazurin to resorufin. Resazurin is dark blue in color until it is 
reduced to resorufin, which is pink. Nonviable cells rapidly lose metabolic capacity, do not 
reduce the indicator dye, and thus do not generate a pink colorimetric signal. The visible light 
absorbance properties of CellTiter-Blue® Reagent undergo a “blue shift” upon reduction of 
resazurin to resorufin. The absorbance maximum of resazurin is 605 nm and that of resorufin 
is 573 nm (after Promega CellTiter-Blue® Cell Viability Assay manual protocol, Promega, 
Germany). Treatment with lysis solution, 2% Triton X-100 (v/v) in PBS, served as negative 
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control. The average of absorbance values of Triton X-100 treated wells was substracted from 
all absorbance values of experimental wells. Interference of Triton X-100 with colorimetric 
signal was excluded before. Data are given as a percentage of control. 
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5 Brain region-specific vulnerability of astrocytes in response to 3-nitropropionic acid 
is mediated by cytochrome c oxidase isoform expression 
5.1 Abstract  
Brain region specificity is a feature characteristic for neurodegenerative disorders, such as 
HD and others. Here, we aimed to study the brain region-specific vulnerability of striatal in 
comparison with cortical and mesencephalic astrocytes treated with NPA, an in vitro model of 
HD. Mitochondrial dysfunction is involved in neurodegenerative processes. We previously 
demonstrated a causal relationship between NPA-induced COX subunit IV isoform 2 
transcription (cox4i2) and increased oxidative stress leading to higher necrotic cell death rates 
in striatal astrocytes by application of a siRNA knockdown system. In this study, we 
investigated the correlation of COX IV-2 protein expression with intracellular ATP content, 
mitochondrial peroxide production and viability of astrocytes from three different brain 
regions. We found that in cortical and mesencephalic astrocytes, NPA caused an elevation of 
cox4i2 transcription as in striatal astroglia. However, only in striatal astrocytes, we observed 
increased COX IV-2 and decreased COX IV-1 protein expression levels. In agreement with 
our hypothesis, striatal astrocytes showed the highest levels of peroxide production and 
necrotic cell death rates in comparison with cortical and mesencephalic astroglia. We, 
therefore, suggest that the higher vulnerability of astrocytes from striatum in our in vitro 
model of HD is, at least in part, based on brain region-specific differences of the COX IV-
2/COX IV-1 protein ratios and accompanied elevated oxidative stress. 
5.2 Introduction  
COX is located in the inner mitochondrial membrane catalyzing the electron transfer from 
ferrocytochrome c to oxygen. Each monomer of the dimeric enzyme complex consists of 
three mitochondria-encoded catalytic and ten nucleus-encoded regulatory subunits (Tsukihara 
et al., 1996; Grossman & Lomax, 1997). The nucleus-encoded COX subunit IV-1 plays a 
crucial role in regulating energy metabolism and oxidative stress (Arnold & Kadenbach, 
1999; Kadenbach et al., 2000; Kadenbach et al., 2004; Horvat et al., 2006; Singh et al., 2009). 
At high intracellular energy levels, ATP binds to the N-terminus of COX subunit IV-1 and 
inhibits the enzyme activity allosterically (Arnold & Kadenbach, 1997; 1999; Horvat et al., 
2006). This regulatory mechanism enables the enzyme to detect the intracellular energy level 
and facilitates the adjustment of ATP production to cellular energy demand. This mechanism 
is conferred to the mammalian enzyme by the ubiquitously transcribed COX isoform IV-1, 
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whereas a second isoform of COX subunit IV (COX IV-2) impedes this regulatory 
mechanism presumably due to differences of the polypeptide sequence at the N-terminal ATP 
binding site of COX subunit IV. COX IV-2 is only marginally expressed in brain tissue as 
well as in astrocytes under physiological conditions. However, under hypoxic and toxic 
conditions this COX isoform IV-2 is up-regulated (Horvat et al., 2006; Singh et al., 2009). 
Cortical astrocytes exposed to hypoxia, i.e. conditions that are equivalent to depriving COX 
of its catalytic substrate, showed an up-regulation of COX IV-2. This in turn prevents the 
allosteric inhibition of COX by ATP and increases COX activity irrespectively of the 
ATP/ADP ratio, thereby suppressing the sensitivity of COX to high cellular energy levels 
(Arnold and Kadenbach, 1997; Horvat et al., 2006). This was the first evidence for an oxygen 
concentration-dependent expression of mammalian COX subunit IV isoforms (Horvat et al., 
2006). Recently, we reported a similar up-regulation of cox4i2 transcripts after treatment of 
striatal astrocytes with NPA for 48 h. The systemic application of NPA is a widely accepted 
in vitro model of HD. Interestingly, the NPA-mediated increase in necrotic cell death rate was 
not accompanied by decreased ATP levels but by an elevation of ROS production. The most 
severely affected brain region in HD is the striatum (Brouillet et al., 1999; Vonsattel et al., 
1985). However, other cerebral regions are also affected in HD patients, especially the 
cerebral cortex, although to a lesser extent (Albin, 1995). With respect to a higher 
vulnerability of neural cells from striatum than from other brain regions, we investigated the 
COX isoform expression, mitochondrial peroxide production and astrocyte viability in 
striatum compared with cortex and mesencephalon. Indeed, we found brain region-specific 
differences with respect to the COX subunit IV isoform expression pattern, mitochondrially 
produced oxidative stress, and necrotic cell death. 
5.3 Materials and methods  
Materials and animals 
All chemicals were obtained from Roth (Karlsruhe, Germany), whereas reagents for 
molecular biological techniques and cell culture were purchased from Invitrogen (Karlsruhe, 
Germany), unless noted otherwise. BALB/c mice were purchased from Harlan Winkelmann 
GmbH (Borchen, Germany). 
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Preparation of primary astrocyte cultures  
Astroglial cultures were prepared from postnatal day 1 BALB/c mice as described in 
section 4.1.1. Cerebral striatum, cortex and mesencephalon derived astrocytes were grown at 
37°C in a humidified atmosphere of 95% air/5% CO2. Culture medium was replaced every 
third day. Before reaching confluence, cells were trypsinized and plated at lower density. Sub-
confluent astrocytes were incubated in complete NBM (section 4.1.1) for 48 h and 
subsequently used for experiments.  
 
Cell treatment  
Primary astrocyte cell cultures from the three different brain regions were placed on 
culture dishes at 37°C in a humidified atmosphere of 95% air/5% CO2. In the presence of 
NBM, cells were treated with NPA (Sigma-Aldrich, Munich, Germany) for the time 
indicated. Cells of the same preparation maintained under the same conditions except for 
NPA treatment served as controls.  
 
Small interfering RNA (siRNA) transfection  
Transfection of cultured astrocytes with siRNA (Ambion, Hundingdon, UK) was carried 
out after the first passage of cells reached a confluence of approximately 85%. To achieve the 
knockdown of COX subunit isoform IV-2, siRNA against cox4i2 was applied (siRNA ID 
175413) like described in section 4.1.4. Transfection efficiency of astrocytes with siRNA 
against cox4i2 of ca. 95% was reached.  
 
Immunocytochemistry  
To verify the purity of astrocytic culture, immunocytochemistry was performed with 
astrocytic marker. Cells grown on PLO-coated coverslips were stained with Hoechst and 
passed through the steps described in section 4.2.5. Primary antibody against GFAP (Encor, 
Gainsville, FL, USA), a specific marker for astrocytes was added to cells. To view the 
presence of GFAP within the cells secondary antibody Alexa Fluor® 488 labelled donkey 
anti-mouse IgG (Invitrogen, Göttingen, Germany) was used. 
 
Apoptosis and necrosis assay 
To distinguish between apoptotic and necrotic astrocytes, siRNA-transfected and non-
transfected, NPA-treated and untreated control cells were cultured on PLO-coated coverslips 
and stained with 3 μM YO-PRO®-1 (Invitrogen) followed by addition of 2 μg/ml Hoechst 
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33342 trihydrochloride (Hoechst; Invitrogen) as described in details in section 4.4.1. Viable 
(Hoechst-positive), early apoptotic (Hoechst-, PI-positive), late apoptotic and necrotic 
(Hoechst-, YO-PRO®-1-, and PI-positive) cell nuclei were scored under a fluorescence 
Axiophot microscope (Carl Zeiss, Oberkochern, Germany) at excitation wavelength of 365 
(Hoechst), 485 (YO-PRO®-1), and 530 nm (PI). Early apoptotic cells showed a YO-PRO®-
1-/PI-positive cytoplasm, whereas late apoptotic were distinguished from necrotic cells by 
their additional YO-PRO®-1-, and PI-positive cytoplasm. Cell nuclei were counted in three 
separate experiments by counting cells in three distinct randomly selected areas per coverslip 
(3x105 μm2 per field) using the NIS-elements AR 3.0 ® software (Nikon, Düsseldorf, 
Germany).  
 
Reverse transcription and real-time PCR 
Total RNA was isolated from treated and/or transfected cells and untreated controls using 
PeqGold RNA pure (PeqLab, Erlangen, Germany) according to manufacturer’s protocol. 
cDNA was synthesized from 1 μg total RNA using MMLV Reverse Transcriptase (section 
4.2.1). For the relative quantification of the COX IV-1 and COX IV-2 in un-treated and NPA 
treated primary striatal, cortical and mesencephalic astrocytic culture, real time PCR was 
performed using SYBR-Green mix (Bio-Rad, Munich, Germany). 18S rRNA and Hprt were 
employed as normalizing genes. The identity of PCR products was confirmed with melting 
curve analysis and agarose gel electrophoresis. For details see section 4.2.2. 
 
Western blot analysis  
Astrocytes were lysed in ice-cold hypotonic RIPA buffer. Proteins were collected and 
measured as described in sections 4.2.3 and 4.2.4. Protein samples (50 μg per lane) were 
loaded onto and separated by 12.5% (v/v) SDS-PAGE and transferred onto a HybondTM 
ECLTM nitrocellulose membrane (Amersham Biosciences, Buckinghamshire, UK). After 
blocking with 5% non-fat milk nitrocellulose membrane was incubated for 24 h at 4°C with 
mouse anti-COX IV-1 antibody (MitoSciences, Eugene, OR, USA), mouse anti-COX IV-2 
antibody (Abnova, Heidelberg, Germany), and rabbit anti-β-actin antibody (Sigma, USA) in 
TBST buffer containing 5% (w/v) non-fat dry milk. Detection was performed with 
peroxidase-conjugated goat anti-rabbit IgG-HRP (Sigma, USA) or rabbit anti-mouse antibody 
(Abcam, Cambridge, UK). Peroxidase activity was visualized using enhanced 
chemiluminescence, ECLTM method (Amersham Biosciences). For semi-quantitative 
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evaluation of protein expression, immunoreactivity signals of protein bands were normalized 
to β-actin signals measured in the same blot.  
 
ATP assay  
The intracellular ATP content of cultured astrocytes was determined using the ATP 
Bioluminescence Assay Kit HS II (Roche, Mannheim, Germany) according to the instruction 
of the manufacturer (see section 4.3.1). The ATP content of the NPA-treated or/and 
transfected cells was calculated and normalized to the amount of proteins determined by 
applying the BCATM Protein Assay Kit (Pierce, Bonn, Germany) with respect to untreated 
controls set as 100% (Singh et al., 2009).  
 
Hydrogen peroxide detection  
Peroxide generation was measured using Amplex Red Hydrogen Peroxide/Peroxidase 
Assay Kit (Invitrogen). Freshly isolated mitochondria from astrocytes (as described in detail 
in Singh et al., 2009 and section 4.3.5) were resuspended in minimal volume of mitochondrial 
buffer and added to 100 μl Krebs-Ringer phosphate buffer containing 50 μM Amplex Red 
reagent and 0.1 U/ml horseradish peroxidase. Hydrogen peroxide in mitochondrial samples 
was detected by formation of resorufin, the fluorescent oxidation product of Amplex Red, 
using a fluorescence microplate reader (Tecan GENios, Crailsheim, Germany). The 
fluorescence of resorufin was excited at 535 nm and its fluorescence emission detected at 595 
nm. Application of distinct H2O2 concentrations (0 – 3 μM) served as a standard to quantify 
sample H2O2 concentrations. Determination of protein in mitochondria was used for 
normalization.  
 
Statistical Analysis  
Data are presented as mean ± SEM of at least three independent experiments (N). For 
statistical analysis, data were analyzed by applying ANOVA followed by a post hoc two-
tailed, independent Student’s t test applying the software SPSS (Chicago, IL, USA). Values 
were regarded as statistically significant when compared to control (*) and to NPA-treated 
samples (#) at ***/### p< 0.001, **/## p < 0.01, */# p < 0.05. 
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5.4 Results  
NPA treatment caused the highest vulnerability in astrocytes from striatum due to 
increased necrotic cell death rates  
Isolated primary astrocytes from mouse (postnatal day 1) brain striatum (Fig. 5A), cortex 
(Fig. 5B) and mesencephalon (Fig. 5C) showed mainly GFAP -immunoreactive cells (> 95%) 
and were virtually free of neurons, oligodendrocytes, and microglial cells. To study brain 
region differences of astrocyte viability and mitochondrial characteristics in an in vitro model 
of HD, we treated primary astrocytes from striatum, cortex, and mesencephalon with 10 mM 
NPA for 48 h. Astrocytes were subsequently analyzed for cell viability, COX subunit IV 
isoform expression, intracellular ATP content and mitochondrial peroxide production. To 
evaluate the specific role of COX isoform IV-2 astrocytes were additionally co-treated with 
NPA and siRNA against cox4i2.  
  
30 µm
C
30 µm
B
30 µm
A
 
 
Figure 5. Immunocytochemical staining of primary astrocytes. Striatal (A), cortical (B) and 
mesencephalic (C) astrocytes in culture are shown under phase-contrast image. Immunocytochemical 
staining was performed with a primary antibody against GFAP and alexa Fluor 488 conjugated 
secondary antibody. Nuclei were visulized after Hoechst staining. Co-staining of Hoechst and GFAP 
confirmed the purity of astrocytic culture.  
 
 
Cell viability was analyzed by different methods of labeling with the fluorescent indicator 
dyes (Fig. 6A-D) Hoechst 33342 (Fig. 6B), YO-PRO®-1 (Fig. 6C), and PI (Fig. 6D). In Fig. 
6A-D, viable (arrow), early apoptotic (star), late apoptotic (arrowhead), and necrotic cells 
(block arrow) are presented. Viable cells (Fig. 6A, arrow) showed an exclusive Hoechst-
positive staining. A Hoechst-staining of apoptotic bodies in cell nuclei combined with a 
nuclear and cytoplasmic staining for PI (red), but an exclusive cytoplasmic YO-PRO®-1-
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staining (green) is characteristic for early apoptotic cells (star). Late apoptotic (arrowhead) 
and necrotic (block arrow) cells showed Hoechst-, YO-PRO®-1-, and PI-positive nuclei. Late 
apoptotic were distinguished from necrotic astrocytes by an additional YO-PRO®-1- and PI-
positive staining of the cytoplasm. Based on the localization and appearance of the fluorescent 
dyes in cell nuclei and cytoplasm, necrotic (Fig. 6E) and apoptotic cells (Fig. 6F) were 
counted and calculated as percentage of total cell number. Cultured astrocytes from all three 
brain regions showed a higher degree of necrotic than apoptotic cell death rates. Striatal 
astrocytes demonstrated the highest necrotic cell death rate in comparison to cortical and 
mesencephalic cells (Fig. 6A). Taking the basal level of necrotic cell death rates in untreated 
astrocytes into account, NPA treatment caused an approximately six-, two-, and three-fold 
increase in striatal, cortical, and mesencephalic cells, respectively. After NPA treatment, the 
apoptosis rates (Fig. 6F) were increased by approximately 100%, 50%, and 250% in striatal, 
cortical, and mesencephalic astroglia, respectively. 
A siRNA-mediated knockdown of cox4i2 transcripts decreased the necrotic cell death 
significantly in astrocytes from all three brain regions (Fig. 6E), but increased the apoptotic 
cell death rate (Fig. 6F) in striatal and mesencephalic cells by approximately 4- and two-fold, 
respectively (Fig. 6B). The NPA-mediated overall cell death rates (Fig. 6G) were highest in 
striatal followed by mesencephalic and cortical astrocytes. Due to the effect of siRNA against 
cox4i2 on apoptosis in astrocytes from striatum and mesencephalon, the co-treatment of 
astrocytes with NPA and siRNA against cox4i2 failed to decrease the overall cell death in 
striatal and mesencephalic astroglia. 
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Figure 6. Astrocytes from striatum showed the highest vulnerability after NPA treatment when 
compared with astroglia from cortex and mesencephalon. (A-D) Astrocytes stained with 
fluorescent viability indicator dyes are presented in a merged picture (A) of Hoechst- (B), YO-PRO®-
1- (C), and PI-stained cells (D). (A-D) Viable (arrow; Hoechst-positive), early apoptotic (star; 
Hoechst-, PI-positive), late apoptotic (arrowhead) and necrotic (block arrow; Hoechst-, YO-PRO®-1-, 
and PI-positive) fluorescent cell nuclei are indicated. Early apoptotic cells showed a YO-PRO®-1-/PI-
positive cytoplasm. Late apoptotic were distinguished from necrotic cells by their additional YO-
PRO®-1- and PI-positive cytoplasm. (E-G) Astrocytes from striatum (striped columns), cortex (grey), 
and mesencephalon (black) were untreated (control), NPA-treated (NPA), or co-treated with NPA and 
siRNA against cox4i2 (NPA + siIV-2). Necrotic (E), apoptotic (F), and overall cell death (G; control 
set 1) was assessed by counting astrocytes differentially stained with fluorescent viability indicator 
dyes. Data represent mean ± SEM (*/#p<0.05, **/##p<0.01, ###p<0.001, N=8) of samples compared 
with control (*) and with NPA-treated cells (#). 
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COX subunit IV isoform transcription and protein expression was affected by NPA in a 
brain region-specific manner  
Astrocytes from all three brain regions showed under normal culturing conditions a 
predominance of cox4i1 transcription (Fig. 7A), whereas cox4i2 was only marginally 
transcribed (Fig. 7B). Treatment of cultured astrocytes from striatum, cortex, and 
mesencephalon with 10 mM NPA for 48 h revealed an approximately four-, eight-, and four-
fold elevation of cox 4i2 transcript levels, respectively (Fig. 7B). The NPA-mediated 
increased cox4i2 transcript levels were decreased to basal levels by co-application of siRNA 
against cox4i2. After NPA treatment, the transcription levels of cox4i1 were decreased in 
striatal astrocytes by approximately 50%, were elevated in cortical astroglia by approximately 
40%, and remained unchanged in mesencephalic cells as a result of the NPA-treatment (Fig. 
7A). A siRNA against cox4i2 exerted no significant effect on the cox4i1 transcription levels. 
The differentially regulated cox4i2 and cox4i1 transcript levels are summarized by presenting 
the cox4i2/cox4i1 ratio (Fig. 7C). The highest NPA-mediated up-regulation of the 
cox4i2/cox4i1 ratio was observed for striatal followed by cortical and mesencephalic 
astrocytes. The co-treatment of astrocytes from all three brain regions with siRNA against 
cox4i2 completely reverted the NPA-mediated increased cox4i2/cox4i1 ratio. The changes in 
the transcription levels of COX subunit IV isoforms were mostly reflected by concomitant 
changes of the COX isoform protein levels (Fig. 8). COX IV-1 and COX IV-2 protein levels 
were normalized to β-actin (Fig. 8A). 
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Figure 7. The transcript ratio of cox4i2 to cox4i1 is increased in striatal astrocytes to the highest 
degree based on an up-regulation of cox4i2 and a down-regulation of cox4i1. Astrocytes from 
striatum (striped columns), cortex (grey), and mesencephalon (black) were untreated (control), NPA-
treated (NPA), or co-treated with NPA and siRNA against cox4i2 (NPA + siIV-2). qRT-PCR revealed 
differently down-regulated cox4i1 (A) and up-regulated cox4i2 transcript levels (B) which was also 
reflected in the cox4i2/cox4i1 transcript level ratio (C) in astrocytes from three brain regions (*). A 
siRNA against cox4i2 decreased cox4i2 transcript levels, whereas cox4i1 was not significantly affected 
when compared with NPA-treated samples (#). Data represent mean ± SEM (*p<0.05, **/##p<0.01, 
***/###p<0.001, N=5).  
 
COX isoform IV-1 is the predominant COX subunit IV isoform expressed under normal 
culturing conditions in astrocytes from all three brain regions (Fig. 8A). The NPA-mediated 
transcriptional increase of cox4i2 and the changes of cox4i1 were also observed on the protein 
level, when the optical densities of Western Blot bands were calculated and compared with 
control protein levels set 100% (Fig. 8). Western blot results showed a COX IV-2 up-
regulation upon NPA treatment by approximately three-fold in striatal (Fig. 8B) and cortical 
(Fig. 8C) and by 50% in mesencephalic astrocytes (Fig. 8D). COX IV-1 protein content was 
down-regulated upon NPA exposure in striatal astrocytes to approximately 40% of control 
levels (Fig. 8B), whereas it was up-regulated by approximately two-fold in cortical astroglia 
(Fig. 8C) and remained unchanged in mesencephalic cells (Fig. 8D).  
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Figure 8. COX IV-1 and COX IV-2 protein expression supported the transcription data of NPA-
induced up-regulation of cox4i2. Astrocytes from striatum, cortex, and mesencephalon were 
untreated (control), NPA-treated (NPA), or co-treated with NPA and siRNA against cox4i2 (NPA + 
siIV-2). (3A) Western blots and (3B-D) calculation of optical density of bands of COX IV-1 (white 
columns) and COX IV-2 (black columns) normalized to β-actin and in comparison with COX isoform 
levels under control conditions set 100% are shown for striatum (B), cortex (C), and mesencephalon 
(D). (3E) Ratios of COX IV-2/COX IV-1 protein levels are presented for astrocytes from striatum 
(striped columns), cortex (grey columns), and mesencephalon (black columns) relatively to control set 
1. (3B-E) Data represent mean ± SEM (*p<0.05, **p<0.01, ***p<0.001, N=4) relative to control set 
100%.  
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Accordingly, the COX IV-2/COX IV-1 ratio demonstrated the highest increase by 14-fold  in 
striatal astroglia, whereas cortical and mesencephalic cells exhibited an increase by 170% and 
45%, respectively (Fig. 8E). A siRNA-mediated knockdown of COX IV-2 efficiently 
decreased the appropriate protein levels not affecting COX IV-1 protein expression levels in 
astrocytes from all brain regions. 
 
NPA caused an elevation of intracellular ATP content and mitochondrial peroxide 
production in astrocytes from all three brain regions, but to a different extent  
Treatment of astrocytes from all brain regions caused an up-regulation of intracellular ATP 
levels (Fig. 9A). The highest elevation of the ATP content by three-fold was detected in 
cortical astrocytes, whereas striatal and mesencephalic astroglia exhibited an increase by 
approximately 20% and 40%, respectively. A COX IV-2 knockdown revealed a diminished 
ATP elevation upon NPA treatment by 10% and 90% in striatal and cortical astroglia, 
respectively, whereas it was further up-regulated by 70% in mesencephalic cells.  
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Figure 9. Intracellular ATP content and peroxide production exhibited highest levels for cortex 
and striatum, respectively. Astrocytes from striatum (striped columns), cortex (grey columns), and 
mesencephalon (black columns) were untreated (control), NPA-treated (NPA), or co-treated with NPA 
and siRNA against cox4i2 (NPA + siIV-2). The values of ATP content and peroxide production were 
calculated relative to control (*) set 100%, compared with NPA-treated samples (#) and represent 
mean ± SEM (*/#p<0.05, **/##p<0.01, ***p<0.001, N=6). 
 
 
The peroxide production was measured as an indicator of increased oxidative stress caused 
by mitochondria (Fig. 9B). We observed in astrocytes from all three brain regions an elevated 
mitochondrial peroxide production which was highest (by 700%) in striatal astrocytes, 
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whereas an increase by 140% and 135% were measured for cortical and mesencephalic 
astroglia, respectively. The NPA-mediated elevation of peroxide production was decreased 
due to a parallel COX IV-2 knockdown by 300%, 65%, and 75% in striatal, cortical, and 
mesencephalic astrocytes, respectively. 
5.5 Discussion  
In a recently published study (Singh et al., 2009), we examined the role of mitochondrial 
structural and functional characteristics of striatal astrocytes in NPA-mediated toxicity. 
Striatal astrocytes were chosen for this in vitro model of HD with respect to the selective loss 
of striatal astrocytes after systemic application of NPA (Nishino et al., 1995). Here, we aimed 
to demonstrate striatum-specific NPA-mediated effects on astrocyte viability in comparison 
with cortex and mesencephalon.  
The cause of neurodegeneration in HD is apparently multifactorial (Cattaneo et al., 2001). 
A number of “initiator” mechanisms have been suggested and include abnormal interactions 
between mutated Htt and neuronal proteins (Cattaneo et al., 2001; Gervais et al., 2002), 
transcriptional dysregulations (Cha et al., 2000; Zuccato et al., 2001), mitochondrial defects 
and oxidative damage (Arnold and Beyer, 2009; Beal 2000; Browne et al., 1997; Panov et al., 
2002; Sawa et al., 1999), and indirect activation of excitotoxic cascade leading to apoptosis 
(Ona et al., 1999; Sanchez et al., 1999; Saudou et al., 1998) or necrosis (Brouillet et al., 1999; 
Singh et al., 2009). Supporting the hypothesis that mitochondrial defects could play a role in 
HD pathogenesis (Beal, 2000; Blum et al., 2003), intoxication with the succinate 
dehydrogenase (SDH) inhibitor NPA in rats and non-human primates produces abnormal 
movements, cognitive deficits and striatal degeneration (Beal, 2000; Blum et al., 2001; 2002; 
Brouillet et al., 1995). Despite the preferential vulnerability of the striatum to NPA toxicity, 
cell loss in certain areas of the cerebral cortex anatomically connected to the striatum has also 
been observed several weeks after onset of striatal degeneration (Mittoux et al., 2002). 
However, brain region-specific differences were not related to a differential effect of NPA on 
SDH activity because the latter was similarly inhibited by NPA in striatal and cortical neurons 
(Galas et al., 2004). We, therefore, focused on the role of COX subunit IV isoform expression 
in energy production, mitochondrially caused oxidative stress, and astrocyte vulnerability in 
striatum compared with cortex and mesencephalon. NPA as an inhibitor of SDH, complex II 
of the mitochondrial respiratory chain, impairs mitochondrial energy production (Ayla et al., 
2007; Beal et al., 2005; Gu et al., 1996; Schapira, 1997). Although we detected an increase in 
vulnerability of mainly striatal when compared with cortical and mesencephalic astrocytes, 
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this was apparently not due to a diminshed ATP content, but rather an elevated peroxide 
production by astrocytic mitochondria. Oxidative damage and metabolic dysfunction have 
been implicated in HD (Browne et al., 1997). The peroxide levels in striatal astrocytes 
exceeded those in cortical and mesencephalic cells by several fold. Surprisingly, the impaired 
astrocyte viability was paralleled by increased instead of the expected decreased intracellular 
ATP levels which were highest in cortical and lowest in striatal astrocytes. This apparently 
reflected the overall cell death rate in NPA-treated astrocytes which was the lowest in cortical 
and highest in striatal astrocytes. A maintained oxidative energy production by the respiratory 
chain during complex II inhibition could, at least in part, be explained by electron entry via 
complex I of the mitochondrial respiratory chain. Supportively, a study by Folbergrová and 
colleagues demonstrated that complex I inhibition was not accompanied by impaired ATP 
production, which was apparently due to excess capacity of complex I documented by energy 
thresholds (Folbergrová et al., 2009). Thus, elevated ROS production seems to be the major 
reason for NPA-mediated cell death in striatal astrocytes. The lowest ATP level together with 
the highest peroxide production in striatal astrocytes could explain the highest level of 
necrotic cell death rates in astrocyte cultures from striatum when compared with cortex or 
mesencephalon.  
NPA-mediated elevated overall cell death rates of striatal astrocytes were rather caused by 
necrosis than apoptosis. This observation of higher necrotic than apoptotic cell death rates 
supports our earlier report on striatal astroglia (Singh et al., 2009) and was observed in 
astrocytes of all three brain regions although to a different extent. Increased necrosis rates 
were accompanied by increased COX IV-2 and decreased COX IV-1 protein levels preceded 
by an up-regulation of cox4i2 and down-regulation of coix4i1 transcript levels, specifically in 
striatal astrocytes. COX isoform IV-1 is the predominant isoform in astrocytes from all three 
brain regions under normal culturing conditions. Cox4i1 transcripts are exchanged for cox4i2 
under hypoxic and toxic conditions (Horvat et al., 2006; Singh et al., 2009). However, more 
important for functional consequences of enzyme activities are protein instead of transcript 
levels. Furthermore, not only the absolute COX isoform IV-2 levels are valuable, but also 
those of COX IV-1. Therefore, we calculated the COX IV-2/COX IV-1 protein ratio in NPA-
treated astrocytes. We found the most prominent elevation of COX IV-2/COX IV-1 in striatal 
astrocytes accompanied by the highest peroxide production and necrotic cell death rate. 
Cortical and mesencephalic cells exhibited much lower COX IV-2/COX IV-1 ratio due to up-
regulated or constant COX IV-1 additionally to increased COX IV-2 levels, respectively. This 
could be the reason for a partial protection of astrocytes from other brain regions than 
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striatum. A COX IV-2-specific knockdown by applying siRNA against this COX isoform 
caused a down-regulation of necrotic cell death rates in all three brain regions indicating a 
causal relationship between COX subunit IV isoform expression pattern and mitochondrial 
peroxide production and necrotic cell death.  
Knockdown of COX IV-2 in the presence of the mitochondrial toxin NPA reverted 
necrotic cell death, but induced an elevation of apoptotic cell death rates in striatal and 
mesencephalic, but not in cortical astrocytes. This observation was not made when a negative, 
unspecific siRNA was applied (data not shown). Transfection of untreated and NPA-treated 
astrocytes with siRNA against one of the COX subunit IV isoforms did neither affect the 
transcription nor the protein expression levels of the other isoform (data not shown). Elevated 
apoptosis rates are, therefore, apparently a specific feature of COX IV-2 knockdown in NPA-
treated astrocytes from striatum and mesencephalon, two very vulnerable brain regions. 
Interestingly, cortex was the only brain region, where astrocytes showed an NPA-mediated 
up-regulation of COX IV-1 protein levels. These data point at a role of increased COX IV-1 
levels under toxic conditions in protecting cells from undergoing apoptosis.  
Interestingly, a switch from cox4i1 to cox4i2 transcription is accompanied by increased 
catalytic activity of COX (Singh et al., 2009). This, in turn, could serve as an explanation of 
increased intracellular ATP content in our experiments. Most of the respiratory chain 
complexes do exhibit a higher capacity than the activity they show under physiological 
conditions. The lowest excess capacity was proposed for COX thereby being the rate-limiting 
enzyme of the respiratory chain (Villani et al., 1998). COX is the sole enzyme of the 
respiratory chain known to be regulated by allosteric factors, such as ATP binding in 
exchange for ADP to the inner mitochondrial domain of COX subunit IV-1 (Arnold and 
Kadenbach, 1997; 1999; Kadenbach and Arnold, 1999). This enables the enzyme to detect the 
ATP level and adjust COX and thus respiratory chain activity to energy demand (Arnold and 
Kadenbach, 1997; Horvat et al., 2006; Singh et al., 2009). The expression of nuclear-encoded 
subunit isoforms provides a basis for fine-tuning the COX activity in response to specific 
metabolic needs in different cell types and tissues. Previously, we have shown a cell type-
specific expression of COX subunit IV isoforms in the brain (Horvat et al., 2006). Thus, the 
ubiquitously and highly expressed COX isoform IV-1 renders astrocytes able to detect 
neuronal energy demand and to adjust oxidative energy metabolism to provide neurons with 
the energy substrate lactate accordingly to the neuron-glia metabolic cooperation (Pellerin, 
2003). However, under hypoxic and toxic conditions, COX isoform IV-2 is up-regulated in 
astrocytes (Horvat et al., 2006; Singh et al., 2009). This isoform exhibits a higher catalytic 
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activity than COX IV-1 at the expense of an abolished sensitivity of the enzyme towards the 
cellular energy level (Horvat et al., 2006; Singh et al., 2009). Another consequence of COX 
IV-2 expression is an elevated mitochondria-produced oxidative stress (Singh et al., 2009). 
This observation was also made for NPA-treated astrocytes from cortex and mesencephalon, 
but to a much lower extent. I correlate this to the lower COX subunit IV isoform ratio in 
astroglia from these two brain regions compared with striatum.  
In conclusion, I found that COX subunit IV isoforms play an essential brain region-specific 
role for mitochondrial energy metabolism, oxidative stress, and consequently survival of 
astrocytes under toxic conditions. NPA-treated astrocytes from striatum showed a higher 
vulnerability than those from cortex and mesencephalon. This provides additional mechanistic 
insights in a brain region-specific role of COX and mitochondria in cell viability under toxoic 
conditions. My observations support the concept of a selective vulnerability of the striatum in 
HD. 
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6 Cytochrome c oxidase isoform IV-2 is involved in 3-nitro-propionic acid-induced 
toxicity in striatal astrocytes 
6.1 Abstract 
Astrocyte mitochondria play an important role for energy supply and neuronal survival in 
the brain. Toxic and degenerative processes are largely associated with mitochondrial 
dysfunction. We investigated the effect of NPA, a mitochondrial toxin and in vitro model of 
HD, on mitochondrial function and viability of primary striatal astrocytes. Although NPA is 
known as an irreversible inhibitor of SDH, we observed an increase of astrocyte ATP levels 
after NPA treatment. This effect could be explained by NPA-mediated alterations of COX 
subunit IV isoform expression. The up-regulation of COX isoform IV-2 caused an increased 
enzyme activity at the expense of elevated mitochondrial peroxide production causing 
increased cell death. The application of a small interfering RNA against COX IV-2 revealed 
the causal implication of COX isoform IV-2 in NPA-mediated elevation of oxidative stress 
and necrotic cell death. Thus, I propose a novel additional mechanism of NPA-induced cell 
stress and death which is based on structural and functional changes of astrocyte COX and 
could indirectly impair neuronal survival. 
6.2 Introduction 
There is a growing body of evidence that mitochondria play a crucial role in toxic and 
neurodegenerative processes (Ayla et al., 2007; Beal, 2005). Several mitochondrial toxins, 
such as NPA, are used as in vitro and in vivo models of neurodegeneration. Chronic and 
systemic administration of NPA as an irreversible inhibitor of SDH to rodents or primates 
causes a selective loss of medium spiny neurons in the striatum (Brouillet et al., 1999; Vis et 
al., 1999). The respective pathology and symptoms are similar to those observed in HD. HD is 
a hereditary neurodegenerative disorder characterized by motor and cognitive deficits. These 
symptoms are associated with a progressive degeneration of GABAergic neurones in the 
striatum and the deep layers of the cerebral cortex (de la Monte et al., 1988; Ferrante et al., 
1987). Although the mechanisms leading to neurodegeneration are unknown, compelling 
evidence indicates that mitochondrial dysfunction occurs quite early in the course of HD and 
can be observed in transgenic models of the disorder (Jenkins et al., 1998; Koroshetz et al., 
1997; Panov et al., 2002; Sawa et al., 1999). Thus, neurodegeneration could result from an 
impairment of oxidative energy metabolism and subsequent indirect excitotoxic neuronal 
damage (Beal, 2005; Brouillet et al., 1999). The primary mechanism underlying NPA-induced 
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striatal toxicity is apparently a selective downregulation of protein expression and inhibition 
of the activity of respiratory chain complex SDH which is consistently found to be reduced in 
the striatum of patients with HD (Browne et al., 1997; Gu et al., 1996; Tabrizi et al., 1999). 
Astrocytes are the predominant cell type in the brain supporting neuronal viability and 
function (Jourdain et al., 2007; Pellerin et al., 2007). Among other important functions, 
astrocytes provide for and regulate energy homeostasis under normal conditions but appear to 
be particularly involved in the modulation of energy metabolism under pathological 
conditions in the central nervous system (de Keyser et al., 2008; Giaume et al., 2007). To 
figure out the contribution of astrocytes for neuronal vulnerability against NPA and in HD, we 
studied the effect of NPA on mitochondrial energy production in primary astrocytes cultured 
from mouse brain striatum. Despite the fact, that NPA primarily affects complex II of the 
respiratory chain, we investigated the terminal enzyme of the respiratory chain, COX. COX is 
a complex enzyme consisting of 13 subunits, three of which are encoded by the mitochondria 
genome and fulfil the catalytic function, whereas ten additional nuclear-encoded subunits 
provide a regulatory potential to the enzyme (Grossman and Lomax, 1997; Kadenbach et al., 
2000). One of the regulatory COX subunits (COX IV) occurs in two isoforms, i.e. COX IV-1 
and IV-2 (Hüttemann et al., 2001). The expression of COX subunit IV-1 isoform renders the 
enzyme sensitive towards the cellular energy level and enables it to couple the rate of ATP 
production to energetic requirements. The underlying mechanism of this regulatory process 
involves the binding of ATP to subunit IV-1 in the presence of a high ATP/ADP ratio, thereby 
causing an allosteric inhibition of COX (Arnold and Kadenbach, 1997; 1999; Horvat et al., 
2006). Expression of COX isoform IV-2, however, prevents this regulatory mechanism 
(Horvat et al., 2006). With respect to the potential role of COX in stress-induced apoptosis 
and degenerative diseases, we aimed to analyze the COX subunit IV isoform expression and 
the related functional consequences on survival of striatal astrocytes after NPA treatment 
(Kadenbach et al., 2004). 
6.3 Material and methods 
Primary striatal astrocytes culture  
Primary astrocytes were prepared from BALB/c mice on postnatal day 1 as described in 
4.1.1. Before reaching confluence, astrocytes were trypsinized and plated at lower density. 
Sub-confluent astrocytes were incubated in NBM for 48 hours and subsequently used for 
experiments.  
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Cell treatment  
Primary neurons placed on culture dishes at 37°C in a humidified atmosphere were treated 
in the presence of different concentrations (1 μM-25 mM) of NPA (Sigma-Aldrich) in NBM 
supplemented with 0.4% (v/v) B27, 50 U/ml penicillin, 50 μg/ml streptomycin, 2 mM L-
glutamine (Glutamax®) for the time interval indicated. Cells of the same preparation 
maintained under the same conditions except for NPA served as controls.  
 
Transfection and small interference (siRNA)-mediated knock-down  
Gene-silencing approach, using siRNA was used to knock-down the COX IV-2 gene. To 
achieve successful knock-down, treated and un-treated striatal astrocytes were transfected 
with optimized siRNA against COX IV-2 (5’-GCGAGUCUAUGUGUUCCCUtt-3’) as 
mentioned in section 4.1.4.  
 
Immunocytochemistry  
To verify the purity of astrocytic culture, immunocytochemistry was performed with 
astrocytic marker. Cells grown on PLO coated coverslips were stained with Hoechst and 
passed through the steps described in section 4.2.5. Primary antibody against GFAP (Encor, 
Gainsville, FL, USA), a specific marker for astrocytes was added to cells. To view the 
presence of GFAP within the cells secondary antibody Alexa Fluor® 488 labelled donkey 
anti-mouse IgG (Invitrogen, Göttingen, Germany) was used.  
 
Cell viability, apoptosis, and necrosis assays  
Cell viability was determined applying the exclusion and Hoechst staining Trypan Blue 
methods. Cells were taken out after treatment, washed with PBS and trypsinised with 0.1% 
trypsin/EDTA. Cells were centrifuged at 300 g for 5 min and pellet was resuspended in 
complete culture medium. 20 μl of suspension was taken and mixed with 5 μl of trypan blue. 
The mixture was left for incubation for 10 min and the cells were counted per ml with the 
help of haemocytometer by using the following formula.  
 
            Cells per ml = the average count per square x the dilution factor x104  
 
Cell viability was presented as percentage of the ratio of unstained (viable) cells to the total 
number of cells (stained and unstained cells). Cells were counted from three distinct areas 
(3x105 μm2 per field) of three independent cell preparations. Viability of control cells was 
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referred to as 100%. To distinguish between apoptotic and necrotic astrocytes, Hoechst and PI 
staining was performed as described in section 4.4.1. 
 
Reverse transcription and real-time PCR  
Total RNA was isolated using PEQGOLD, reverse transcribed (section 4.2.1). cDNA was 
amplified and analyzed for starting amount as described in section 4.2.2. For the relative 
quantification of the COX IV-1 and COX IV-2 in un-treated and NPA treated primary striatal 
astrocytic culture, real time PCR was performed using SYBR-Green mix (Bio-Rad). 18S 
rRNA and Hprt were employed as normalizing genes. The identity of PCR products was 
confirmed with melting curve analysis and agarose gel electrophoresis.  
 
ATP assay  
Intracellular ATP content of cultured cells was determined using the ATP 
Bioluminescence Assay Kit HS II (Roche, Mannheim, Germany) according to manufacturer´s 
instructions. Details have been provided in section 4.3.1. ATP content was calculated and 
normalized to the number of viable cells with respect to un-treated controls set as 100%.  
 
Glycogen assay  
Glycogen content of astrocytes was determined using Glycogen Assay Kit (BioVision, 
Mountain View, CA, USA) accordingly to manufacturer’s instructions. The colorimetric 
measurement was performed in a microplate reader (Tecan GENios) by detecting the 
absorbance at 570 nm. Glycogen content was calculated using a glycogen standard; untreated 
controls were set as 100%. Protein content was used for normalization (section 4.3.3).  
 
Mitochondrial isolation and polarographic measurements  
Mitochondria were isolated from treated and un-treated striatal astrocytes and frozen in -80 
degree as suggested in section 4.3.4. Thawed aliquots of frozen isolated mitochonbdria served 
as samples for polarographic measurements to determine COX kinetics (vmax and Km in the 
presence of ADP or ATP including an ATP regenerating system). The detailed procedure for 
polarographic measurement has been mentioned in section 4.3.6.  
 
Hydrogen peroxide detection in mitochondria  
Peroxide generation in mitochondria was measured using Amplex Red Hydrogen 
Peroxide/Peroxidase Assay Kit (Invitrogen). Mitochondria were isolated as described in 
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section 4.3.4. The isolation needed to be fast and on cold temperature throughout (on ice). The 
isolated mitochondria were instantaneously measured for peroxide production as described in 
4.3.5. 
6.4 Results 
Treatment of striatal astrocytes with NPA causes an impairment of cell viability 
To assess the role of mitochondria in toxic processes, cultured astrocytes were treated with 
the NPA in a time and concentration-dependent way. A high rate of cell death was observed, 
when cells were treated with 10 mM NPA for 48 h (Fig. 10B/C). Staining of striatal astrocytes 
with Trypan Blue and Hoechst revealed approximately 10% cell death in the astroglial cell 
population under normal culturing conditions, whereas treatment of cells with 10 mM NPA 
caused an elevation of cell death up to 30% after 48 h (Fig. 10A). Applying different methods 
for identifying necrotic and apoptotic cell death, i.e. staining of cells with Trypan Blue (Fig. 
10A), Hoechst (Fig. 10A/B/C), and propidium iodide, similar results were obtained. Cell 
treatment for 24 h or longer showed no difference in the rate of cell death (Fig. 10A/B), 
whereas NPA at a concentration higher than 10 mM caused a significant increase of apoptotic 
but no further significant elevation of necrotic cell death rates (Fig. 10C). For the following 
studies, a concentration of 10 mM NPA was applied for 48h. Necrotic cell death occurred in 
NPA-treated astrocyte cultures to a higher degree than apoptosis as determined by staining 
cells with Hoechst and propidium iodide (Fig. 10B/C). Approximately 20% of astrocytes were 
undergoing necrotic cell death, whereas ca. 8% of cells were dying from apoptosis. Under 
control conditions, necrosis was slightly more pronounced than apoptosis.  
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Figure 10. Viability of primary striatal astrocytes is impaired after NPA treatment. (A) The 
percentage of viable primary striatal astrocytes was decreased after 24 and 48 h treatment with 10 mM 
NPA when compared to untreated astrocytes. Viability was assessed by staining astrocytes with 
Trypan Blue (white columns) and Hoechst 33342 (black columns). The number of untreated and 
treated viable cells was counted and expressed as % of total cell number undergoing the experiment. 
(B/C) Hoechst-stained astrocytes were analyzed for apoptosis (grey columns) and necrosis (black 
columns). Both, apoptosis and necrosis, were increased after NPA treatment with necrosis showing a 
higher percentage of cell death. Data represent mean ± SEM (*p<0.05, **p<0.01, N=8).  
 
 
COX subunit IV isoform transcription and enzyme kinetics are affected by NPA  
To study the effect of NPA on structural and functional aspects of the terminal 
mitochondrial respiratory chain enzyme, COX subunit IV isoform transcription was analyzed 
in astrocytes untreated and treated for 48 h with 10 mM NPA (Fig. 11A-C) and with NPA at 
different concentrations (Fig. 11D/E). Real time-PCR (RT-PCR) analysis revealed a higher 
basal transcription level of COX IV-1 in comparison to COX IV-2 under normal conditions, 
whereas significant changes in the transcription of COX isoforms IV-1 and IV-2 occurred 
after 10 mM or 25 mM NPA for 48 h (Fig. 11A/B, D/E). COX IV-1 transcription after 10 mM 
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NPA for 48 h was decreased by approx. 50% and a 4-fold increase was seen for COX IV-2 
(Fig. 11A/B). However, neither the treatment of astrocytes with 10 mM NPA for 1 h with a 
subsequent incubation period under control conditions for further 47 h nor an incubation time 
shorter than 24 h in the presence of NPA at concentrations lower than 10 mM were sufficient 
to induce significant changes in the transcription levels of COX subunit IV isoforms. The 
antidromic change in COX IV isoform transcription after 48 h of NPA exposure led to an 
approx. 8-fold increase of the COX IV-2/COX IV-1 ratio (Fig. 11C).  
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Figure 11. NPA induced an up-regulation of COX IV-2 transcripts and a down-regulation of 
COX IV-1 transcripts. COX IV-1 and IV-2 transcript levels were quantified by qRT-PCR after 
treatment of striatal astrocytes for 48 h with 10 mM NPA (A-C) and at different NPA concentrations 
(D/E). Transcription levels were normalized to 18S rRNA and compared with untreated control cells 
(*p<0.05, **p<0.01, ***p<0.001, N=5). (A) NPA treatment showed a maximal decrease of COX IV-1 
transcription form 1.4 to 0.7 after 48 h NPA treatment, whereas (B) COX IV-2 transcription reached 
maximal increase from 0.4 to 1.5 after 48 h of NPA treatment. (C) COX IV-2/COX IV-1 ratio showed 
a 7.5-fold increase after 48 h treatment of cells with NPA compared with the isoform ratio in untreated 
control cells set 1. (D/E) Treatment of astrocytes with NPA at concentrations of 10 mM and 25 mM 
caused maximal decrease of COX IV-1 (D) and maximal increase of COX IV-2 transcription (E).  
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Various concentrations of NPA treatment showed similar results as obtained for NPA-
induced changes of astrocyte viability which evokes that COX subunit IV isoform 
transcription reached highest levels after 48 h of cell treatment with 10 mM or 25 mM NPA. 
As previously shown for astrocyte COX regulation under hypoxia, changes in the COX 
subunit IV isoform expression pattern caused significant alterations in the kinetic parameters 
of COX (Horvat et al., 2006). Therefore, mitochondria isolated from treated and untreated 
astrocytes were solubilised and COX activity was assessed. To mimic COX activity at a high 
cellular energy level, oxygen consumption of solubilised mitochondria was measured in the 
presence of 5 mM ATP, whereas a low cellular energy level was mimicked by addition of 5 
mM ADP. COX from untreated astrocytes showed a hyperbolic curve of the enzyme turnover 
numbers (TN) in dependence on cytochrome c concentrations and in the presence of ADP, 
whereas a sigmoid curve was presented in the presence of ATP (Fig. 12A/B). This reflects the 
allosteric inhibition of COX by ATP at high energy levels, i.e. at physiological cytochrome c 
concentrations of 2 μM (van Beek-Harmsen & van der Laarse, 2005) COX activity was 
inhibited.  
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Figure 12. Treatment of astrocytes with NPA induced a change of the COX kinetics 
characteristics of COX. (A, B) Ascorbate-stimulated COX activity of solubilized mitochondria 
isolated from striatal astrocytes treated with 10 mM NPA for 48 h (grey symbols and lines) and from 
untreated control cells (black symbols and lines) was measured polarographically at increasing 
concentrations of cytochrome c (N=8). COX activity was measured in the presence of 5 mM ATP 
(squares) and 5 mM ADP (circles). Data are given as TN (consumed O2 [IM]/total protein [mg] x s). 
(B) represents an insert of (A) to better visualize the allosteric inhibition of COX at physiologically 
relevant cytochrome c concentrations.  
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The allosteric feature of COX inhibition by ATP is further substantiated by a Hill 
coefficient of 1.9 in the presence of ATP (Fig. 13C). With decreasing ATP/ADP ratios we 
observed a decrease of the Hill coefficient down to approximately 1.28 in the presence of 
ADP. Furthermore, the maximal TN of COX (vmax) at the highest substrate concentration of 
50 μM cytochrome c was decreased in the presence of ATP by approximately 50% when 
compared to ADP-stimulated respiration (Figs. 12A, 13A). Km of COX for cytochrome c was 
approximately 4-fold lower in the presence of ADP than in the presence of ATP (Fig. 13B).  
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Figure 13. Treatment of astrocytes with NPA caused changes of the kinetic characteristics of 
COX. Ascorbate-stimulated COX activity of solubilized mitochondria from striatal astrocytes treated 
with 10 mM NPA for 48 h (NPA) and from untreated control cells (Control) were measured 
polarographically in the presence of ADP (grey columns) and ATP (black columns) as described in 
Fig. 3. (A) Maximal turnover numbers are presented. Data are given as TN (consumed O2 [IM]/total 
protein [mg] x s) at 50 IM cytochrome c. (B) The Michaelis–Menten constant and (C) the Hill 
coefficient were calculated for COX kinetics. Data are presented as mean ± SEM (*p<0.05, **p<0.01, 
NPA-treated samples vs. untreatedcontrols; #p<0.05, ##p<0.01, kinetic characteristics measured in the 
presence of ADP vs. ATP; N=8).  
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These kinetic COX characteristics were significantly changed after treatment of striatal 
astrocytes with 10 mM NPA for 48 h NPA-treated astrocytes exhibited an overall increase in 
COX activity independently of the ATP/ADP ratio (Fig. 13A). In the presence of ADP, vmax 
of COX was increased by 28%, whereas it was elevated by 50% in the presence of ATP. This 
was accompanied by a 25% and 20% increase of the Km of COX for cytochrome c in the 
presence of ATP and ADP, respectively (Fig. 13B). Whereas the Hill coefficient remained 
unchanged for COX of untreated vs. treated astrocytes in the presence of ADP, we observed a 
significant decrease in the presence of ATP from 1.9 to 1.4 (Fig. 13C). This is equivalent to 
an abolition of the allosteric COX inhibition in the presence of high ATP/ADP ratios.  
 
NPA-induced increases of COX activity was accompanied by elevated intracellular ATP 
levels at the expense of a higher peroxide production  
Furthermore, I studied the effect of NPA on the intracellular energy level by measuring the 
ATP level. Treatment of astrocytes with NPA at concentrations of 10 mM or higher and for 
24 or 48 h caused an elevation of ATP in viable cells by approximately 20% (Fig. 14A/B). 
This increase in ATP was paralleled by an approximately 7-fold elevation of mitochondrial 
peroxide production (Fig. 14C). Additionally, the glycogen content of astrocytes was 
measured after NPA treatment to evaluate the metabolic status of astrocytes. An insignificant 
decrease of glycogen by approximately 7% was detected (data not shown).  
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Figure 14. Intracellular levels of ATP and mitochondrial peroxide production were elevated 
after NPA treatment of astrocytes. (A/B) The intracellular ATP levels measured by applying an 
ATP bioluminescence assay kit were increased by ca. 20% after 24 and 48 h of NPA treatment of 
primary striatal astrocytes (A) at a concentration of 10 mM and 25 mM (B). (C) Mitochondrial 
peroxide production detected as a measure of reactive oxygen species in astrocytes was 7-fold 
increased upon 10 mM NPA treatment for 48 h. Data were compared to untreated control samples set 
100% (dotted lines; *p<0.05, ***p<0.001, N=4). 
 
 
Elevated COX isoform IV-2 transcription is causally correlated with elevated oxidative 
stress and necrotic cell death of NPA-treated striatal astrocytes  
In order to reveal that elevated COX IV-2 transcript levels in astrocytes treated with 10 
mM NPA for 48 h are causally linked to the observed changes in the ATP and peroxide 
production as well as cell viability, a siRNA approach against COX IV-2 was applied. In a 
first attempt, the efficiency of the siRNA application was scrutinized by RT-PCR revealing a 
down-regulation of COX IV-2 transcript levels from approximately 400% after NPA 
treatment to ca. 40% when striatal astrocytes were treated with siRNA against COX IV-2 for 
 65
24 h prior to NPA exposure for 48 h (Fig. 15B). The application of siRNA against COX IV-2 
did not exert any significant effects on the down-regulated COX IV-1 transcription levels 
detected after NPA treatment (Fig. 15A). Treatment of astrocytes with scrambled siRNA as a 
negative control caused only marginal changes in COX IV-1 or IV-2 transcription.  
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Figure 15. Application of siRNA against COX subunit isoform IV-2 showed a knock-down of 
this isoform in NPA-treated astrocytes. COX IV-1 (A) and COX IV-2 (B) transcription levels were 
quantified by qRT-PCR after treatment of striatal astrocytes with 10 mM NPA for 48 h in the absence 
(NPA) and presence of siRNA against COXIV-2 (NPA+siIV-2) and compared to untreated control 
samples (control; **p<0.01, N=5). Applying siRNA against COX IV-2 to NPA-treated astrocytes 
caused a down-regulation of COX IV-2 below basal transcription level in untreated control cells, 
whereas no changes in COX IV-1 transcription were observed.  
 
 
Subsequently, the intracellular ATP levels and mitochondrial peroxide production were 
assessed (Fig. 16A and B, respectively). The knock-down of COX IV-2 led to a decrease of 
NPA-induced intracellular ATP elevation from 117% to 107% (Fig. 16A). This was paralleled 
by a decrease of mitochondrial peroxide production from 700% to 400% after knock-down of 
COX IV-2 (Fig. 16B). The down-regulation of elevated ATP and peroxide production was 
paralleled by a decrease of necrotic cell death of NPA-treated striatal astrocytes by 
approximately 50% (Fig. 16C).  
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Figure 16. Knock-down of COX isoform IV-2 improved astrocyte survival during NPA 
treatment by diminishing ROS production. Astrocytes were assessed for (A) intracellular ATP, (B) 
peroxide production, and (C) Hoechst-stained necrotic cell death. Data are calculated as percentage of 
ATP (A) and peroxide production (B) in treated compared to untreated control cells set 100%. 
Necrotic cell numbers (C) are given as percentage of the total cell number. All data are presented as 
mean ± SEM (*p<0.05, **p<0.01, NPA-treated samples vs. untreated controls; #p<0.05, NPAand 
siRNA-treated samples vs. NPA-treated samples; N=5). Knock-down of COX IV-2 caused a down-
regulation of ATP and peroxide production as well as necrotic cell death. 
 
 
6.5 Discussion  
NPA-mediated toxicity resembles one of the toxin-induced models which have been 
generated in addition to transgenic and knock-in animal models to study the pathogenic 
mechanisms of HD (Ramaswamy et al., 2007). Despite the availability of these different 
models, it is still unclear as to why medium spiny striatal neurons selectively die in HD. One 
possible mechanism of cell death in mutant Htt transgenic models and drug-induced mouse 
models involves mitochondrial abnormalities of neurons (Browne et al., 1997; Gellerich et al., 
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2008; Gu et al., 1996; Schapira, 1997; Tabrizi et al., 1999). To mimic mitochondrial 
dysfunction, NPA is used both in vitro and in vivo to model acute insults such as ischemia as 
well as neurodegenerative disorders including HD and AD (Ayla et al., 2007; Beal, 2005; 
Geddes et al., 2000).  
Previous studies focused mainly on neurons, although it recently became more evident that 
astrocytes play a crucial role for neuronal survival under toxic and degenerative conditions 
(Kipp et al., 2006; Maragakis and Rothstein, 2006). Essential functions of astrocytes which 
are important in this context include the maintenance of the “neuronal milieu” including 
energy homeostasis (Barres, 1991). Neuronal loss can result from direct action of the toxin on 
neurons or indirectly through an involvement of astrocytes. In the absence of astrocytes, 
neurons are more prone to the effects of mitochondrial toxins and excitotoxic damage (Dugan 
et al., 1995). This indicates a crucial role for astrocytes in supporting neuronal function and 
survival.  
To examine the potential role of astrocyte mitochondria function in NPA-mediated 
neuronal toxicity and with respect to maximal effects obtained for cell death rate and COX 
subunit IV isoform transcription pattern, 10 mM NPA for 48 h was applied to cultured striatal 
astrocytes. The striatum have been chosen, since this brain region is most affected in HD. Our 
findings of an increased cell death rate after NPA treatment is in agreement with the 
observation of a selective loss of striatal astrocytes after systemic application of NPA 
(Nishino et al., 1995). Preliminary experiments on NPA-treated astrocytes from cortex 
support the observations of a higher vulnerability of striatal in comparison with cortical 
astroglia providing additional mechanistic insights in a brain region-specific role of COX and 
mitochondria in cell viability under toxic conditions (manuscript submitted). Additionally, we 
provide evidence of a more pronounced necrotic than apoptotic death of striatal astrocytes. 
NPA as an inhibitor of SDH, the complex II of the mitochondrial electron transport chain, is 
known to cause an impairment of mitochondrial energy production in neural cells (Ayla et al., 
2007; Beal, 2005; Gu et al., 1996; Schapira, 1997). On the other hand, both necrosis and 
apoptosis are generally associated with impaired energy metabolism and could, therefore, 
explain the decreased survival of neural cells treated with NPA (Sawa et al., 2003). Indeed, an 
increased cell death after NPA treatment has been correlated with diminished energy 
production due to decreased respiratory chain enzyme activity (Beal, 2005; Sawa et al., 2003). 
Surprisingly, we observed elevated instead of decreased ATP levels. One explanation, why 
others reported an ATP decrease under similar conditions of treatment could be due to the 
normalization procedure of results on the ATP amount in cells in my study. ATP levels were 
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correlated to the number of viable cells surviving the treatment rather than the total number of 
cells initially used for the experiment or the protein amount determined after NPA treatment 
which are used in other studies. An observation made by Esfandiari and colleagues 
demonstrating that SDH is only partially inhibited in astrocytes treated with 3 mM NPA for 4 
h indicates that mitochondrial energy metabolism is not completely blocked by NPA and 
supports our data (Esfandiari et al., 1997). Taken into account that electrons enter the 
respiratory chain of mitochondria also at complex I, higher energy production can be 
assumed. Therefore, we suspected an involvement of COX, the terminal enzyme of the 
mitochondrial electron transport chain, and have analyzed the transcription pattern of COX 
subunit IV isoforms along with the kinetic characteristics of this enzyme.  
After NPA treatment, the enzyme exhibited an increased catalytic activity due to a switch 
in COX subunit IV isoforms from COX IV-1 to COX IV-2 in striatal astrocytes. 
Mechanistically, the changes of the catalytic properties of COX can be explained by an 
abolition of ATP/ADP binding to the N-terminus of COX subunit IV. COX is well known for 
its complex regulation by adenine nucleotides and hormones (Arnold and Kadenbach, 1997; 
1999; Arnold et al., 1998). An allosteric regulatory mechanism of COX activity has been 
demonstrated for COX isoform IV-1 at high energy levels in our earlier studies (Arnold and 
Kadenbach, 1997; 1999; Horvat et al., 2006). It indicates a crucial role for COX in sensing the 
cellular energy level and being able to couple it to mitochondrial ATP production (Horvat et 
al., 2006). This mechanism is a specific feature of astrocyte COX but not occurring in neurons 
(Horvat et al., 2006). The reason for this may be a different COX IV isoform expression 
pattern in both brain cell types. The regulatory COX isoform IV-1 is expressed ubiquitously 
including astrocytes and neurons, but neurons do also reveal considerable COX IV-2 
expression. Astrocytes only show marginal transcription of COX IV-2, an observation that 
holds true for astrocytes from different brain regions. Under hypoxic conditions, however, 
astrocytes demonstrate a significant induction of COX IV-2 transcription which is 
accompanied by an abolition of the allosteric COX inhibition by ATP (Horvat et al., 2006). In 
the present report, we demonstrate a similar up-regulation of COX IV-2 paralleled by a down-
regulation of COX IV-1 transcripts after 48 h of NPA treatment of striatal astrocytes. This 
indicates that COX subunit IV isoform transcription is regulated also by toxic and not only by 
hypoxic stimuli. The NPA-mediated increased COX IV-2 transcription was also accompanied 
by an abolishment of the allosteric inhibition of COX by ATP at high energy levels. This is 
supported by a decrease of the Hill coefficient, a measure of the cooperativeness of two 
substrate binding sites at the dimeric COX enzyme, from approximately 2 for COX in 
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untreated astrocytes to approximately 1.5 in NPA-treated astrocytes. Thus, the enzyme is no 
longer able to detect the energy level and couple it to the ATP production. Irrespectively of 
the energy level (presence of ATP or ADP), astrocytic COX exhibited a higher catalytic 
activity (vmax) after NPA treatment of astrocytes than under normal cell culturing conditions. 
This could serve as an explanation for the observed rise of intracellular ATP. However, the 
switch from COX IV-1 to COX IV-2 transcription is, paradoxically, also accompanied by an 
increase in peroxide production which, in turn, explains the elevated necrotic cell death of 
striatal astrocytes after NPA treatment despite an increased cellular ATP level. Previously, we 
suggested that an abolition of the allosteric COX inhibition at high ATP/ADP levels could 
cause an increased production of reactive oxygen species (ROS) due to an elevated 
mitochondrial membrane potential (Lee et al., 2001). Thus, our finding of NPA-mediated 
COX isoform IV-2 transcription, which prevents from the allosteric COX inhibition by ATP, 
supports the role for COX isoform IV-2 in oxidative stress. Generally, an increased COX 
activity is assumed to decrease the oxidative stress by decreasing the ROS production that is 
caused by a block of the electron transfer at complex III and I (Cadenas et al., 1977). 
However, recent reports suggest a role for an elevation of COX activity in ROS production 
(Dröse and Brandt, 2008). Thus, a higher COX electron transfer onto oxygen causes the 
ubiquinone pool to be oxidized to a higher degree, thereby enabling complex III to transfer 
electrons to oxygen and increase the oxygen radical production. 
To examine in more detail the metabolic status of mitochondria, we measured the glycogen 
content. Although the astrocyte glycogen content was only marginally decreased after NPA 
treatment, this change could point at glycogen as a source for anaerobic ATP generation 
additionally to the utilization of exogenous glucose provided in the cell culture medium. 
Supportively, Dringen and colleagues (Wiesinger et al., 1997) considered glycogen in 
astrocytes as a store for generating lactic acid rather than glucose. This could serve as an 
additional factor for NPA-mediated increased ATP levels. Furthermore, NADPH regeneration 
by pentose phosphate pathway utilizing glycogen irrespective of exogenous glucose is 
essential for the activity of the glutathione redox cycling (Rahman et al., 2000), a mechanism 
important for protecting cells from oxidative stress. An activation of this antioxidant pathway 
may explain the relatively limited cell death rate despite the high rate of mitochondrial ROS 
production. The impairment of mitochondrial energy production and increased ROS 
production are two pathways that are widely accepted mechanisms involved in 
neurodegeneration (Ayla et al, 2007; Beal, 2005).  
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Here, we show that NPA treatment of striatal astrocytes did not increase cell death by a 
reduction of energy production rather by an increase in ROS production. The causal 
implication of COX isoform IV-2 was verified by the application of siRNA against COX IV-
2. This attenuated the NPA-mediated increase of COX activity, ATP levels, and ROS 
production. Our data highlight the crucial role for the COX isoform IV-2 in NPA-induced 
elevation of oxidative stress and necrotic cell death. This could affect proper astroglia 
function under pathological conditions and, in turn, indirectly impair neuronal survival. In our 
opinion, future studies of neurodegeneration should comprise local astroglia considering not 
only their basal supportive function for neurons but equally deciphering the action of toxins 
and pathological processes on this cell type. Stabilizing and improving astrocytic function 
may have a tremendous impact on neuronal survival in the brain. 
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7 Gender-specific role of mitochondria in the vulnerability of 6-hydroxydopamine-
treated mesencephalic neurons  
7.1 Abstract 
Many neurodegenerative diseases, such as Morbus Parkinson, exhibit a gender-dependency 
showing a higher incidence in men than women. Most of the neurodegenerative disorders 
involve either causally or consequently a dysfunction of mitochondria. Therefore, neuronal 
mitochondria may demonstrate a gender-specificity with respect to structural and functional 
characteristics of these organelles during toxic and degenerative processes. The application of 
6-OHDA in vitro and in vivo represents a well accepted experimental model of PD causing 
Parkinsonian symptoms. Besides the known effects of 6-OHDA on mitochondria and 
neuronal survivability, we aimed to demonstrate that the mitochondrial neurotoxin affects the 
morphology and survival of primary mesencephalic neurons in a gender-specific manner by 
influencing the transcription of mitochondrial genes, ATP and ROS production. Our data 
suggest that cell death in response to 6-OHDA is primarily caused due to increased oxidative 
stress which is more pronounced in male than in female mesencephalic neurons. 
7.2 Introduction 
The incidence of many neurodegenerative diseases, such as PD, correlates well with 
gender (van den Eeden et al., 2003). Thus, PD occurs 1.5 times more frequently in men than 
in women (Dluzen & McDermott, 2000; Fahn & Sulzer, 2004; Wooten et al., 2004; Haaxma 
et al., 2007). In women, the age at onset of PD correlates with the duration of the fertile life 
(Ragonese et al., 2006; Rocca et al., 2008). PD is a progressive disorder characterized by a 
profound loss of dopaminergic neurons in the mesencephalic substantia nigra pars compacta 
with a marked depletion of striatal dopamine. The resulting striatal deficiency leads to the 
parkinsonian syndrome of bradykinesia, rigidity, tremor, and motor and postural instability 
(Bernheimer et al., 1973; Marsden, 1990). Although the etiology of PD remains unknown, an 
accumulating body of evidence in experimental models of PD and in postmortem tissues of 
sporadic forms of PD suggests that mitochondrial dysfunction due to an impairment of 
mitochondrial energy production and subsequent oxidative stress may be involved. The 
identification of specific gene mutations and their influence on mitochondrial functions has 
further emphasized the relevance of mitochondrial abnormalities in the disease pathogenesis 
(Banerjee ey al., 2009).  
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It is still under debate whether respiratory chain deficiency is etiological in PD. However, 
ample data strongly suggest that toxin-induced respiratory chain disruption per se is sufficient 
to trigger the death of nigrostriatal neurons and to cause PD-like symptoms in animals and 
humans. Interestingly, experimental models comprise the application of inhibitors of 
respiratory chain complex I, such as 6-OHDA, its metabolized toxic form MPP+, or rotenone. 
This points at a specific role of complex I herein and further reinforces the role of 
mitochondria in neurodegeneration. These complex I inhibitors and neurotoxins inhibit ATP 
synthesis in mitochondria causing a loss of ATP and, moreover, stimulate ROS production by 
mitochondria (Andreyev et al., 2005). The selective toxicity of 6-OHDA to dopaminergic 
neurons in the SNc was explained by the fact that 6-OHDA is selectively accumulated and 
subsequently oxidized to produce hydrogen peroxide, superoxide, and hydroxyl radicals in 
these cells (Cohen & Heikkila, 1974; Graham et al., 1978). Besides complex I, 6-OHDA has 
been shown to also inhibit complex IV in vitro (Glinka & Youdim, 1995). In vivo 
administration of 6-OHDA causes a parkinsonian condition characterized by decreasd 
dopamine levels and tyrosine hydroxylase (TH) activity, impaired dopamine uptake, and 
ensuing loss of dopaminergic neurons. Given the parallels with PD, the mechanism by which 
this compound leads to neuronal cells death is of great interest. The gender-specificity of 6-
OHDA-mediated effects has been demonstrated in a rat model, where male rats were more 
susceptible to 6-OHDA than females showing less dopaminergic cell loss and a higher degree 
of behavioral recovery (Tamás et al., 2006). However, a gender-specific disturbance of 
mitochondrial function and energy metabolism has not been demonstrated yet. We, therefore, 
studied mitochondrial structural and functional characteristics along with the survival of their 
neuronal hosts isolated from mouse brain mesencephali as the brain region being most 
affected in PD.  
7.3 Materials and methods 
Preparation of primary mesencephalic neuron cultures 
Primary neurons were prepared from mesencephali of BALB/c mouse brains at GD 14/15 
and cultured as described previously in section 4.1.2. Preapred mesencephalic neuronal 
cultures were maintained at 37°C in a humidified atmosphere of 95% air/5% CO2. After 24 h, 
the cell medium was deprived of FCS. This procedure typically yields neuron-enriched 
cultures containing >90% neurons, of which ca. 2-3% were dopaminergic (TH-positive) cells, 
and <10% astroglial cells. 
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Cell treatment 
Primary neurons were treated with 25 µM and 50 µM 6-OHDA (Sigma-Aldrich) for 24 h. 
Cells of the same preparation maintained under the same conditions except for 6-OHDA 
treatment served as controls. To study a possible recovery of cell viability, neuron cultures 
were incubated for additional 48 h post-toxin treatment in complete NBM medium under 
normal culturing conditions. Protective effects of 17β-estradiol (E; Sigma-Aldrich) at a 
concentration of 10-7 M were studied by pre-application for 3 h and/or co-application of E 
with 6-OHDA for 24 h. 
Fluorescence immunocytochemistry 
Mesencephalon- derived primary neurons cultured on PLO-coated coverslips (Menzel, 
Braunschweig, Germany) were detected by immunocytochemical staining as described in 
section 4.2.5. Primary antibodies against TH (Abcam, Cambridge, UK), NeuN (Chemicon 
Temigula, CA, USA), active caspase 3 (Abcam), and SMI 311 and SMI 312 (Covance, 
Berkeley, CA, USA) and the appropriate secondary Alexa Fluor® 488- or Alexa Fluor® 594-
labeled anti-mouse or anti-rabbit antibodies were used for performed study. Cells were 
examined using a fluorescence Axiophot microscope (Carl Zeiss, Oberkochern, Germany) 
equipped with the software NIS-elements AR 3.0 ® (Nikon, Düsseldorf, Germany) at 
excitation wavelengths of 365±12 nm (Hoechst), 450-490 nm (Alexa Fluor® 488) and 530-
585 nm (Alexa Fluor® 594) or using a confocal LSM 7 DUO microscope (Carl Zeiss) 
equipped with the software ZEN 2009 at the appropriate laser wavelength to excite the 
respective fluorophors.  
Lactate dehydrogenase (LDH) activity assay 
In order to estimate cell death, the level of lactate dehydrogenase (LDH) released from 
damaged cells into culture media was measured by detecting the enzyme activity at 24 h after 
treatment with 6-OHDA. A colorimetric assay was applied as described in section 4.4.2. The 
absorbance was measured at a wavelength of 490 nm. Data were normalized to LDH activity 
released from Triton X-100-treated control cells set 100% of cell death. 
 
Apoptosis and necrosis assays 
To distinguish between apoptotic and necrotic neurons, 6-OHDA-treated and untreated 
control cells were cultured on PLO-coated coverlips and stained with a combination of 
Hoechst 33342, propidium iodide and active caspase 3. For the detail description see section 
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4.4.1. Viable, apoptotic (Hoechst- and active caspase 3-positive), and necrotic (Hoechst- and 
PI-positive) cell nuclei were scored under a fluorescence Axiophot microscope (Carl Zeiss) at 
excitation wavelength ranges of 365±12 nm (Hoechst), 450-490 nm (Alexa Fluor® 488), and 
530-585 nm (PI). Cell nuclei of three independent experiments were counted in three distinct 
and randomly selected areas (3x105 µm2 per field) per cover slip using the NIS-elements AR 
3.0 ® software. Data are presented as percentage of control set 100%. 
Cell viability assay 
To estimate the number of viable cells surviving the 6-OHDA treatment without or with a 
subsequent 48 h recovery period in complete NBM medium thereafter, primary neuronal cells 
were cultured in 96 well plates and analyzed with the fluori- and colorimetric CellTiter-Blue® 
Cell Viability Assay (Promega, Madison, WI, USA) applying manufacturer’s protocol as 
described in section 4.4.3. The CellTiter-Blue® Reagent was added to cells seeded in a 96 
well plate and incubated at 37°C for 1 h. The fluorescence emission at 590 nm was recorded 
at an excitation wavelength of 560 nm in a microplate reader (Victor, 1420 Multilabel 
Counter, Perkin Wallac GmbH, Freiburg, Germany). Cells lysed with 2% (v/v) Triton X-100 
in PBS served as negative control. Data are given as percentage of control set 100%. 
Reverse transcription and real-time PCR 
Total RNA was isolated from treated and/or transfected cells and untreated controls using 
PeqGold RNA pure (PeqLab, Erlangen, Germany) according to manufacturer’s protocol. 
cDNA was synthesized from 1 μg total RNA using MMLV Reverse Transcriptase (section 
4.2.1). Relative quantification of catalytic and regulatory subunits of respiratory chain 
complexes in un-treated and 6-OHDA treated female or male primary mesencephalic neuronal 
culture was performed using SYBR-Green mix (Bio-Rad, Munich, Germany). Forward and 
reverse primers for specific amplification of mitochondria-encoded subunits of the respiratory 
chain complexes: ND1 (complex I), cytB (complex III), cox2 (complex IV) ATP6 (complex 
V) and of nucleus-encoded complex IV subunits isoform cox4i1 and cox4i2 were designed 
eliminating the possibility of amplifying genomic DNA. 18S rRNA and Hprt were employed 
as normalizing genes. The identity of PCR products was confirmed with melting curve 
analysis and agarose gel electrophoresis. For details see section 4.2.2. 
Western blot analysis 
For immunoblotting, primary mesencephalic cultures were lysed in ice-cold hypotonic 
RIPA buffer and proteins were collected as described in section 4.2.3. Protein samples (30 μg 
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per lane) were loaded onto and separated by 12.5% (v/v) SDS-PAGE and transferred onto a 
HybondTM ECLTM nitrocellulose membrane. Non-specific binding sites on the membrane 
were blocked by incubating for 30 min in 5% (w/v) non-fat dry milk in TBST buffer. 
Membrane was then incubated for 24 h at 4°C with mouse anti-COX IV-1 antibody 
(MitoSciences, Eugene, OR, USA), mouse anti-COX IV-2 antibody (Abnova, Heidelberg, 
Germany), and rabbit anti-β-actin antibody (Sigma, USA) in TBST buffer containing 5% 
(w/v) non-fat dry milk. Detection was performed with peroxidase-conjugated goat anti-rabbit 
IgG-HRP (Sigma, USA) or rabbit anti-mouse antibody (Abcam, Cambridge, UK). Peroxidase 
activity was visualized using enhanced chemiluminescence, ECLTM method (Amersham 
Biosciences). For semi-quantitative evaluation of protein expression, immunoreactivity 
signals of protein bands were normalized to β-actin signals measured in the same blot. 
ATP assay 
The intracellular ATP content of cultured neurons was determined using the ATP 
Bioluminescence Assay Kit HS II (Roche, Mannheim, Germany) according to the instructions 
of the manufacturer. Detailed process has been provided in section 4.3.1. The ATP content of 
NPA-treated cells was calculated and normalized to protein content of viable cells with 
respect to untreated controls set as 100%. 
Intracellular reactive oxygen species detection 
ROS measurement was done as suggested in section 4.3.2. Primary neurons were cultured 
in 96-well plates at a density of 5x104 cells/well. After treatment with or without NPA for 24 
h, cells were loaded with 10 μM H2DCFDA diluted in PBS buffer and incubated for 45 min at 
37°C. The fluorescence intensity of DCF after excitation of the samples at a wavelength of 
485 nm was measured. 
Statistical analysis  
Data are presented as mean ± SEM of at least three independent experiments. For 
statistical analysis, data were analyzed by applying ANOVA followed by a posthoc two-
tailed, independent Student’s t test applying the software SPSS (Chicago, IL, USA). Values 
compared to controls (*) and a comparison of female vs. male values (#) were regarded as 
statistically significant at ***/###p<0.001, **/##p<0.01, */#p<0.05. 
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7.4 Results 
Mesencephalic neurons from male mice showed a higher vulnerability than those from 
female mice 
Primary neuronal cultures from mouse brain mesencephali (GD 14/15) consisted of mainly 
NeuN-immunoreactive cells. In figure 17, a representative mesencephalic neuronal culture 
labeled with Hoechst 33342 for cell nuclei (Fig. 17C) and stained for NeuN (Fig. 17B) are 
presented. The majority of cells (≥ 90%) represented neurons visualized by co-staining of 
more than 90% of cell nuclei with a neuronal marker NeuN (Fig. 17A-C). Hoechst-stained, 
but not NeuN-stained non-neuronal elements including astrocytes were only marginally 
present. Merged pictures of Hoechst-stained nuclei with NeuN and TH -immunostained 
dopaminergic neurons revealed less than 5% TH-positive neurons (Fig. 17D) of the total 
number of neurons (Fig. 17A).  
Merged TH
NeuN Hoechst
A D
B C
 
Figure 17. Immunocytochemical staining of primary mesencephalic neuron culture showed 
≥90% neuronal and less than 5% TH-positive neuronal immunoreactivity. The purity of primary 
neuron cultures from mouse brain mesencephali was analyzed after Hoechst-staining of cell nuclei (C) 
by immunocytochemical staining against NeuN (B) and TH (D) visualized after labelling with Alexa 
Fluor® 488 and Alexa Fluor® 594, respectively. A representative merged picture (A) of Hoechst-
stained nuclei (blue) with NeuN- (green) and TH-(red) immunostained cells revealed highly purified 
neuron cultures with non-neuronal impurities to an extent of less than 10% (bars 500 µm). The number 
of TH-positive neurons (D) did not exceed 5% (A). 
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Neuron cultures were treated with the mitochondrial toxin 6-OHDA in a time- and 
concentration-dependent manner. The most commonly applied concentration of 6-OHDA 
falls in the range between 10 to 50 µM.  
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Figure 18. Mesencephalic neurons from males showed a higher vulnerability to 6-OHDA than 
neurons from females. Primary cultures of female (grey columns) and male mesencephalic neurons 
(black columns) were incubated with 25 µM and 50 µM 6-OHDA for 24 h. Apoptotic (A) and necrotic 
cells (B) were counted by caspase 3- (green) and PI-positive staining (red), respectively (C). Viable, 
apoptotic, and necrotic cells were distinguished by the appearance of Hoechst-stained nuclei (blue, C). 
The number of apoptotic and necrotic cells (between 100-500 cells in three distinct and randomly 
selected areas per cover slip of three independent experiments) was calculated and expressed as x-fold 
increase of apoptotic/necrotic cell numbers compared to control conditions set 1. Significant gender-
specific differences (#) were observed for apoptotic and necrotic cell death rates at both concentrations 
of 6-OHDA except for necrotic cell death rates at 25 µM 6-OHDA. Data represent mean ± SEM 
(**/##p<0.01, ***p<0.001, N = 8). 
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Accordingly, we observed half-maximal increases of cell death rates in the neuronal 
population which account for an approximately two- to four-fold increase after treatment with 
25 and 50 µM 6-OHDA for 24 h compared to untreated control cells (Figs. 18, 19; additional 
data not shown).  
A predominance of neuronal apoptosis compared with necrosis became obvious in cells of 
both genders after treatment with 25 and 50 µM 6-OHDA for 24 h (Fig. 18A-C). Staining of 
untreated mesencephalic neurons of both genders revealed approximately 5% of apoptotic and 
10% of necrotic cells with the total cell number set 100%. Under control conditions, apoptotic 
and necrotic cell death rates were both regardless of the gender. However, a gender-specificity 
was detected after treatment of cells with the mitochondrial toxin. Female and male 
mesencephalic neurons treated with 50 µM 6-OHDA exhibited an approximately 3- and 4-
fold increase of apoptotic cell death rates, respectively (Fig. 18A). Necrotic cell death rates of 
female and male cells treated with the same concentration of 6-OHDA were increased by 
approximately 2- and 4-fold, respectively (Fig. 18B). Overall, male neurons exhibited an 
approximately 1.5- to 2-fold higher number of apoptotic and necrotic cells than female cells.  
The LDH assay, a measure of total (apoptotic and necrotic) cell death, performed on 
mesencephalic neuron cultures treated with 50 µM 6-OHDA for 24 h also revealed a higher 
vulnerability of male vs. female neurons (Fig. 19A), whereas the 6-OHDA-mediated decrease 
of metabolic capacity measured with the CellTiter-Blue® Cell Viability Assay demonstrated 
no significant gender-specific differences (Fig. 19B). After treatment of neurons with 6-
OHDA, cells were able to an only partial recovery of metabolic capacity/cell viability when 
incubated for additional 48 h in complete NBM medium after toxin exposure (Fig. 19B). 
 
Neuronal vulnerability was reflected by shortening of neurites of TH-positive cells 
Additionally to a decreased number of viable cells (Fig. 19C-E, F/G, I/J), the application of 
6-OHDA caused concentration-dependent morphological changes. Besides the degradation of 
cell bodies, equivalent to the degree of cell loss, a prominent reduction and/or shortening of 
neurites (Fig. 19I-K) compared to untreated cells (Fig. 19F-H) were detected by high 
resolution confocal microscopy. Staining of mesencephalic neurons against TH and with 
neurofilament-specific antibodies (SMI 311/SMI 312) showed a punctured structure of 
neurites of dopaminergic (Fig. 19J, red) and non-dopaminergic neurons (Fig. 19K, green), 
respectively, when treated with 50 µM 6-OHDA. The punctured structure and shortening of 
TH- and SMI-immunoreactive neurites were considered as a qualitative marker of neurite 
destruction. These changes were more pronounced in male than in female cell cultures (data 
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not shown). In untreated culture, dopaminergic and non-dopaminergic neurons exhibited a 
highly developed net of TH- and neurofilament-immunostained processes (Fig. 19G,H), 
whereas neurons treated with 50 µM 6-OHDA showed a considerable loss of neurofilament 
and neurites (Fig. 19J,K).  
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Figure 19. Gender-specific vulnerability of mesencephalic neurons upon 6-OHDA treatment was 
accompanied by a shortening of neurites of TH-positive neurons. (A) Treatment of neurons with 
50 µM 6-OHDA for 24 h caused a three- to four-fold increased LDH release which was significantly 
higher in male (black columns) than in female cell cultures (grey columns). (B) The metabolic 
capacity measured with the CellTiter-Blue® Cell Viability Assay in cells treated with 50 µM 6-OHDA 
demonstrated no gender-specific differences. The viability of toxin-treated neurons was not 
significantly improved by a subsequent 48 h recovery period in complete NBM medium. The 
percentage of dead cells in the LDH assay was compared with cells in total (dead and viable cells) set 
100%. The cell viability assay shows the percentage of viable cells compared with untreated control 
cells referred to as 100%. Data represent mean ± SEM (*/#p<0.05, ***p<0.001, N = 7). (C-K) Neuron 
cultures were stained with Hoechst for cell nuclei (blue), and immunostained against TH (red), and 
NeuN (green; C-E; bars 20 µm) or Pan- and axonal neurofilament SMI 311 and SMI 312 to highlight 
neuronal processes (green; H, K). The pictures represent an overlay of 10 consecutive confocal z-
images taken as a stack to be able to track neurites in full length in the cell monolayer. (F, I) Phase 
contrast pictures are shown. Additionally to a decreased number of viable cells, equivalent to an 
increased number of apoptotic and necrotic cell nuclei (blue; D, E, J), the application of 6-OHDA 
caused a destruction of neurites of dopaminergic and non-dopaminergic neurons (I-K; bars 100 µm) 
compared to untreated neurons (F-H).  
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To semi-quantitatively evaluate the destruction of neuronal processes the density of total 
fluorescence (green and red for non-dopaminergic and dopaminergic processes, respectively) 
was measured in three confocal pictures from three different experiments. Preliminary data 
revealed that approximately 70% of neuronal non-dopaminergic processes were degraded, 
whereas TH-positive neurons showed an up to 90% loss of neurites. 
Gene transcription of mitochondria- and nucleus-encoded subunits of respiratory chain 
complexes was decreased by 6-OHDA 
The mitochondrial toxin 6-OHDA applied at 50 µM for 24 h induced a significant down-
regulation of transcription levels of representative mitochondria-encoded catalytic subunits of 
respiratory chain complexes (Fig. 20A): ND1 (NADH-ubiquinone oxidoreductase, complex I, 
EC 1.6.5.3.), cytB (ubiquinol-cytochrome c-reductase, complex III, EC 1.10.2.2), and ATP6 
(ATP synthase, complex V, EC 3.6.3.14.). Real time-PCR (RT-PCR) analysis revealed a more 
pronounce down-regulation of ND1 and ATP6 transcript levels in male than in female cell 
cultures, whereas cytB was decreased in both genders to the same extent. Transcription levels 
of COX (complex IV, EC 1.9.3.1.) subunit cox2 remained unchanged and did not reveal any 
gender specificity. With respect to the high regulatory potential of COX, we tested the 
transcription level of one of the regulatory and nucleus-encoded enzyme subunits, COX 
subunit IV. This subunit is expressed in two isoforms (COX IV-1 and COX IV-2). The 
isoform COX IV-1 is known to be sensitive to the cellular energy level, whereas COX IV-2 is 
unable to detect the ATP levels. Therefore, COX IV-1 and IV-2 expression levels are of 
special interest. Similar basal transcription levels of cox4i1 and cox4i2 under normal culturing 
conditions were demonstrated for female and male mesencephalic neurons, whereas 
significant changes in the transcription pattern of these two COX subunit IV isoforms 
occurred after treatment with 6-OHDA.  
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Figure 20. 6-OHDA induced decreased transcription levels of mitochondria-encoded catalytic 
subunits of respiratory chain complexes and a down-regulation of nucleus-encoded cox4i2 
transcripts. Primary female (grey columns) and male neurons (black columns) in culture were 
incubated in the presence of 50 µM 6-OHDA for 24 h. Total RNA was isolated and first strand cDNA 
was synthesized. A qRT-PCR was performed and PCR products were analyzed using the relative ΔCt 
method. The PCR signals of ND1, cytB, cox2, ATP6 (A) and cox4i1, cox4i2 transcripts (B) were 
normalized to 18S rRNA and compared with untreated control cells referred to as 100%. Data 
represent mean ± SEM (*/#p<0.05, **p<0.01, ***p<0.001, N = 7). In (C), Western blot analysis of 
COX IV-1 and COX IV-2 of neuronal lysates supports the results of transcription studies by 
demonstrating a 6-OHDA-induced down-regulation of COX IV-2 in female and male cells, whereas 
COX IV-1 protein remained unchanged relative to β-actin used as control (C).  
The transcription level of cox4i1 remained unchanged, but cox4i2 transcription was decreased 
by approximately 70% (Fig. 20B). Western blot analysis of COX IV-1 and COX IV-2 subunit 
isoforms in neuronal lysates supported the results of the transcription analysis. It 
demonstrated a 6-OHDA-induced down-regulation of COX IV-2 in female and male cells, 
whereas COX IV-1 protein remained unchanged relative to β-actin used as control (Fig. 20C). 
Interestingly, the protein, but not the transcript expression of COX IV-1 revealed 
approximately 3-fold higher levels in control cells from male than female cells.   
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Intracellular ATP and ROS levels were increased in a gender-specific manner upon 6-
OHDA treatment 
To estimate whether a decrease of respiratory chain subunits would affect neuronal 
vulnerability by influencing mitochondrial energy production, the intracellular ATP level was 
assessed. Surprisingly, treatment of neurons with 50 µM 6-OHDA for 24 h caused an 
elevation of intracellular ATP by approximately 50% in females and 20% in male neurons 
(Fig. 21A). The observed ATP levels were higher in female than male cells. As cells with a 
high level of ATP are generally assumed to be protected from degenerative processes we 
analyzed the oxidative stress as a possible reason of the 6-OHDA-mediated increased cell 
death. We observed that the increase in ATP was accompanied by an approximately 30% and 
60% elevation of ROS in female and male neuron cultures, respectively (Fig. 21B). This in 
turn could account for the gender-specific elevated apoptotic and necrotic cell death in 
mesencephalic neuron cultures (Figs. 18, 21C).  
 
Estrogen exerted a neuroprotective effect on 6-OHDA-induced elevated ROS levels and cell 
survival 
The differences between female and male cultures were reflected by a predominance of 
male vs. female neurons undergoing 6-OHDA-induced cell death. This suggests an 
involvement of gender-specific steroid hormones in the survivability of these cells. We 
therefore studied the effect of E on 6-OHDA-treated mesencephalic neurons. E known for its 
wide range of protective functions has been applied prior to and in parallel with 6-OHDA to 
female and male neuron cultures (Figs. 21A-C). Although a change in ATP levels by 100 nM 
E was not detected (Fig. 21A), ROS levels were significantly down-regulated in cultures from 
both genders (Fig. 21B). Exhibiting a gender-specific effect, the ROS level in female cultures 
reached basal level, whereas in male cultures, it showed a remaining elevation of ROS above 
control cell level. Although the ROS levels reached after 6-OHDA treatment differ in male 
and female cells, E decreased the ROS levels to the same extent in neurons of both genders. 
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Figure 21. Intracellular levels of ATP and ROS were altered after 6-OHDA treatment in 
primary neuron culture in a gender-specific manner. Female (grey columns) and male (black 
columns) mesencephalic neurons were analyzed regarding the intracellular ATP (A) and ROS (B) 
levels. (A) The intracellular ATP levels measured by applying an ATP bioluminescence assay kit were 
increased by ca. 50% in females and ca. 20% in male cells after 24 h of 6-OHDA treatment of primary 
neurons. (B) Intracellular ROS levels were elevated by ca. 30% in female and ca. 60% in male neurons 
treated with 50 µM 6-OHDA. (C) Treatment of neurons with 50 µM 6-OHDA for 24 h caused an 
approximately 3-fold increased LDH release which was significantly higher in male (black columns) 
than in female cell cultures (grey columns). (A-C) Pre-treatment of cells with 100 nM 17β-estradiol 
(E) for 3 h and subsequent co-application of E with 6-OHDA (6-OHDA + E) did not affect ATP levels 
(A) which were increased in the presence of the toxin, but decreased, at least in part, toxin-mediated 
elevated ROS levels (B; §) and cell death (C; §). The gender-specific differences remained the same 
for ATP, ROS levels and cell death as in toxin-treated cell cultures. Data were normalized to ATP and 
ROS levels in control cells set 100% (*). The precentage of LDH-releasing dead cells is compared to 
LDH released from cells in total by lysis set 100% (*). Data show a comparison of females vs. males 
(#) and a comparison of 6-OHDA- with E-co-treated cells (§). Data represent mean ± SEM 
(*/#/$p<0.05, ***p<0.001, N=5).  
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A co-treatment of E with 6-OHDA alone did not improve cell survival, whereas a pre-
treatment of cells with 100 nM E for 3 h before the co-treatment of E with the toxin for 24 h 
increased the neuron survival by approximately 5% in female and 15% in male cell cultures 
(Fig. 18C). The cell viability was significantly elevated by the E treatment although cell death 
rates were still approximately 2-fold increased compared with control levels (Figs. 21C, 19A). 
 
7.5 Discussion 
Mesencephalic neuron cultures are mainly comprised of cells other than dopaminergic 
neurons. Accordingly, our neuron cultures showed the presence of approximately 5% TH-
positive cells among more than 90% neuronal cells (Fig. 17). The neurotoxin 6-OHDA 
competes with the dopamine uptake via the plasma membrane transporter and should 
therefore be specific for dopaminergic neurons, thus the smaller percentage of cells in the 
culture (Decker et al., 1993). However, the toxin also impairs the survivability of non-
dopaminergic neurons (Lotharius et al., 1999). The low number of dopaminergic/TH-
immunoreactive neurons in our cell culture system, but the high percentage of cells 
undergoing apoptosis and necrosis after treatment with 6-OHDA suggest dopaminergic and 
non-dopaminergic neurons being affected by 6-OHDA alike (Fig. 18). We applied 6-OHDA 
at a concentration and time range (50 µM for 24 h) that are commonly used for in vitro 
toxicity experiments reaching half-maximal effects on cell death rates (Fig. 18, 19) (Lotharius 
et al., 1999).  
We detected predominantly apoptotic cell death in 6-OHDA-treated mesencephalic 
neurons, although necrotic cell death was also found (Fig. 18B). A number of in vitro and in 
vivo studies have suggested that 6-OHDA triggers death of mesencephalic/dopaminergic 
neurons via apoptosis (Lotharius et al., 1999; Perier et al., 2005). Whereas necrotic cell death 
is mostly associated with ATP loss, a less severe dysfunction of mitochondria with a constant 
or marginally diminished ATP level initiates apoptosis (Simpkins et al., 2009). Surprisingly, 
6-OHDA induced an increase instead of the expected decrease of ATP levels in 
mesencephalic neuron cultures (Fig. 21A) which could, however, explain the higher rates of 
apoptosis compared with necrosis (Fig. 18). Nevertheless, mitochondrial oxidative 
phosphorylation is essential for neurons to meet their high ATP demand. Therefore, neuronal 
viability is imperiled when this ATP production is even transiently diminished. Generally, in 
addition to bioenergetic crisis, mitochondrial impairment also produces a concomitant 
increase in ROS production, which seems to be the primary reason for cell death occurring in 
my experiments (Fig. 21B).  
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Mitochondria represent both a target for cell death and a source for cytotoxic oxygen 
radicals. Accordingly to previous reports, 6-OHDA generates bursts of ROS by blocking 
complex I (Lotharius et al., 1999). This is consistent with our results (Fig. 21B) and data from 
Ramsay and Singer (Ramsay & Singer, 1992) showing that partial ubiquinone oxidation 
resulting from MPP+ blockade of complex I can lead to superoxide formation in 
submitochondrial particles. During further toxin exposure the accelerated mitochondrial 
radical production impedes oxidative phosphorylation via inactivation of Fe-S clusters within 
the respiratory chain. Furthermore, 6-OHDA causes alterations in membrane permeability, a 
decline in mitochondrial membrane potential, and calcium influx akin to excitotoxic cell death 
processes. Such a model would predict superoxide production and a loss of ATP (White & 
Reynolds, 1996). Our data of increased ROS (Fig. 21B), secondary to complex I inhibition, 
and increased apoptosis rates (Fig. 18A) support this, except for the increased ATP levels we 
observed (Fig. 21A).  
The sources of ATP rising under these conditions above control levels could be either 
mitochondrial and/or glycolytic. An inhibition of glycolysis by application of deoxyglucose 
together with blocking the ATPase by oligomycin and inhibiting COX by cyanide caused 
decreased ATP levels in control cells indicating that anaerobic glycolytic as well as oxidative 
mitochondrial energy production are both involved in the ATP increase (data not shown). 
Unlike increased ATP levels decreased transcript levels of representative mitochondria-
encoded, catalytic subunits of the respiratory chain complexes I, III, and V were found (Fig. 
20A) which should additionally lead to decreased respiratory chain activity besides its 
blockade at complex I by 6-OHDA. In favor of decreased mitochondrial transcript levels in 
PD are observations where mutations or other variations in mitochondrial DNA have been 
implicated in the development of PD (Huerta et al., 2005). An impaired mitochondrial DNA 
transcription by ablation of the mitochondrial transcription factor A (TFAM) in nigrostriatal 
dopaminergic neurons caused a progressive loss of dopaminergic neurons due to reduced 
mitochondrial DNA expression and respiratory chain deficiency (Ekstrand et al., 2007). We 
suggest that the observed increased ATP levels represent an early phase of 6-OHDA toxicity, 
where ATP levels are additionally supported by glycolytically derived ATP and which would 
lead to the expected loss of ATP at a later stage of toxin exposure. Supporting this idea, we 
considered that although the transcript levels were decreased, the protein levels may still be 
maintained to fulfill proper mitochondrial energy production in the absence of the 
mitochondrial toxin. Supportingly, the half-life of mitochondrial proteins is equal to 
approximately three days (Saikumar & Ramakrishna Kurup, 1985). Thus, although 
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mitochondrial transcription levels are decreased, protein levels are apparently preserved for 
the duration of 6-OHDA treatment. Furthermore, most of the respiratory chain complexes do 
have a higher capacity than the activity they show under normal conditions. The lowest excess 
capacity was proposed for COX thereby being the rate-limiting enzyme of the respiratory 
chain (Villani et al., 1998) Thus, if COX subunits were down-regulated, an immediate effect 
on the respiratory chain activity should be expected. However, the transcription levels of 
neither the mitochondria-encoded cox2 (Fig. 20A) nor the nucleus-encoded cox4i1 were 
significantly decreased (Fig. 20B), a prerequisite of guaranteed maximal COX activity. Since 
the other respiratory chain complexes are apparently expressed at excess capacity, their 
expression should be down-regulated until this reserve is depleted to influence the overall 
respiratory chain activity.  
COX is the sole enzyme of the respiratory chain known to be regulated by allosteric 
factors, such as ATP binding in exchange for ADP to the inner mitochondrial domain of COX 
subunit IV-1 (Arnold & Kadenbach, 1997; Arnold & Kadenbach, 1999; Kadenbach & Arnold, 
1999). This enables the enzyme to detect the ATP level and adjust COX and thus respiratory 
chain activity to energy demand (Arnold & Kadenbach, 1997; Horvat et al., 2006; Singh et 
al., 2009). The expression of nuclear-encoded subunit isoforms provides a basis for fine-
tuning the COX activity in response to specific metabolic needs in different cell types and 
tissues. Previously, we have shown a cell type-specific expression of COX subunit IV 
isoforms in the brain (Horvat et al., 2006). The ubiquitously expressed COX isoform IV-1 
renders astrocytes able to detect neuronal energy demand and to adjust oxidative energy 
metabolism to provide neurons with the energy substrate lactate accordingly to the neuron-
glia metabolic cooperation (Pellerin, 2003). However, meeting the high energy demand of 
neurons another isoform of COX subunit IV, COX IV-2, is expressed in neurons. The isoform 
COX IV-2 exhibits a higher catalytic activity than COX IV-1 at the expense of an abolished 
sensitivity of the enzyme towards the cellular energy level (Horvat et al., 2006; Singh et al., 
2009). In mesencephalic neurons, the transcript and protein expression levels are higher for 
COX IV-2 than COX IV-1 (transcription data not shown). The presence of COX IV-1 and 
COX IV-2 enables these neurons to catalyze the enzyme reaction at maximal activity plus 
being able to sensitize the cellular energy level. Treatment of mesencephalic neurons with 6-
OHDA caused a decrease of cox4i2 transcription (Fig. 20B) and COX IV-2 protein levels 
(Fig. 20C), whereas cox4i1 transcription and COX IV-1 protein expression remained 
unchanged (Fig. 20B), thereby constraining maximal COX activity. 
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A maintained oxidative energy production by the respiratory chain during complex I 
inhibition could, at least in part, be explained by electron entry via complex II. A recent study 
by Folbergrová and colleagues demonstrated that complex I inhibition was not accompanied 
by impaired ATP production, which was apparently due to excess capacity of complex I 
documented by energy thresholds (Folbergrová et al., 2009). Thus, elevated ROS production 
seems to be the major reason for cell death in mesencephalic neuron cultures. Neurons which 
were kept for an additional period of 48 h in complete NBM medium after 24 h of 6-OHDA 
treatment did not reveal any significant signs of cell recovery indicating that the toxin-treated 
cells reached the “point of no return” on their the cell death pathway (Fig. 19B). A longer 
exposure to 6-OHDA or a higher toxin concentration could promote the ATP loss at a later 
stage and further increase cell death (Klawitter et al., 2009). ATP depletion had also been 
ruled out as a cause of selective neurotoxicity of rotenone in rodents (Sherer et al., 2003). 
Another study that casts doubt upon the generally accepted notion that complex I is the 
primary mechanism of toxicity of PD-linked neurotoxins employs the rotenone toxicity rat 
model combined with a viral delivery of an alternative NADH dehydrogenase (Ndi1). This 
enzyme does not generate a proton gradient but catalyzes NADH oxidation, thereby 
protecting dopaminergic neurons from cell death and decreasing oxidative stress in these cells 
(Marella et al., 2008). 
The increased oxidative stress due to 6-OHDA exposure caused morphological changes of 
mesencephalic neurons, especially a degradation of neurites (Fig. 19D/E, J/K). This loss of 
neuritis affected dopaminergic and non-dopaminergic neurons. 
With respect to the gender-specificity of PD, the applied viability assays (Figs. 18, 19) 
revealed a higher vulnerability of male compared with female mesencephalic neurons. 
Overall, male neurons exhibited an approximately 1.5- to 2-fold higher number of apoptotic 
and necrotic cells reflecting the incidence of PD. The underlying mechanisms of a higher 
vulnerability of male vs. female neurons could be due to higher ROS levels and a more 
pronounced down-regulation of mitochondrial gene transcription, especially the subunits ND1 
and ATP6 of complex I and V, respectively (Fig. 20A). This in turn could account for a more 
diminished respiratory chain activity and subsequently lower ATP levels in the male 
compared with female cells (Fig. 21).  
6-OHDA apparently increases oxidative stress, in addition to its effect on complex I. 
Native antioxidant supplements including reduced glutathione, its precursor N-acetylcysteine, 
vitamin E, the enzyme superoxide dismutase have all been neuroprotective in experimental 
PD models (Davidson et al., 2001). Besides their antioxidant effects estrogens are sex steroids 
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that have a plethora of effects on a wide range of tissues. This female hormone acting as a 
neuroprotectant suggests a basis for the gender differences in PD (Dluzen & McDermott, 
2000). In the mature central nervous system, this hormone has a considerable activity on 
neural cell metabolism and plasticity, as documented by several studies carried out in vivo 
(Arnold & Gorski, 1984) and in vitro (McEwen, 1997). E involvement in neuroprotection is 
widely accepted, although the specific molecular and cellular mechanisms of E action remain 
obscure.  
Estrogens are considered neurotrophic for dopaminergic neurons of the nigrostriatal system 
promoting the growth of TH-positive neurites, increasing TH expression in the neonate mouse 
midbrain and enhancing differentiation and survival of dopaminergic neurons derived from 
human neonatal stem cells (Reisert et al., 1987; Ma et al., 1993; Agrati et al., 1997; Beyer & 
Karolczak, 2000; Sawada & Shimohama, 2000; Ivanova & Beyer, 2003; Kishi et al., 2005; 
Kipp et al., 2006). Additionally, in in vitro and in vivo models of PD, estrogen protects 
dopaminergic cells from toxic compounds, such as 6-OHDA (Dluzen, 1997) and MPP+ (Bains 
et al., 2007). A schematic illustration (Fig. 22) summarizes protective estrogen effects on 
mitochondria, particularly interactions between E and/or estrogen receptors and mitochondrial 
genes, proteins, and function.  
                    
Respiratory
chain
Enzymes
ER
E
ATP
ROS
E E
ΔΨm
Bcl-2, Bcl-xL
Apop-
tosis
mRNA
ER
E
TOX
TOX
 
Figure 22. Schematic illustration of interactions between toxins (TOX) and estrogen (E) with 
mitochondrial genes, proteins, and function. Toxins (TOX; purple) impair mitochondrial and 
nuclear gene transcription of mitochondrial respiratory chain enzymes, thereby affecting ATP 
production and causing increased ROS levels which, in turn, cause elevated cell death rates. On the 
contrary, estrogen (E; blue) affects the expression of mitochondrial proteins by regulating the 
transcription of mitochondrial and nuclear genes promoting mitochondrial ATP and preventing from 
ROS production. Furthermore, E affects the mitochondrial membrane potential (ΔΨm) and pro- and 
anti-apoptotic proteins (Bcl-2, Bcl-xL). Thus, E protects cells from apoptotic or other cell death 
pathways in an estrogen receptor (ER)-dependent and –independent manner. 
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Estrogen affects the expression of mitochondrial proteins by regulating transcription of 
mitochondrial and nuclear genes which are followed by increased respiratory chain activity 
(Bettini & Maggi, 1992; Chen et al., 2003; Scheller & Sekeris, 2003; Araújo et al., 2008; 
Arnold et al., 2008; Irwin et al., 2008) and protection of cells from oxidative stress and 
(apoptotic) cell death (Wang & Phang, 1995; Garcia-Segura et al., 1998; Chen et al., 1999; 
Wang et al., 2001; Arnold & Beyer 2009). Here, we show that E counteracts 6-OHDA-
induced increase of ROS levels thereby decreasing cell death rates of mesencephalic neurons 
(Fig. 21C). However, we did not observe any gender-specific effect of E on 6-OHDA-treated 
male vs. female mesencephalic neurons. This indicates that the protective effects of E occur 
rather due to a locally in the brain synthesized hormone instead of the hormone that is 
systemically distributed and provided to the cells. 
While mitochondrial impairment can be a consequence as well as a primary cause of PD, 
mitochondrial dysfunction is clearly involved in progressive neuronal death in PD and as such 
holds the promise as a potential target for the development of new therapeutic strategies of 
this, currently incurable, disease. 
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8 General discussion 
Analysis of postmortem brain tissue from patients as well as experimental studies in 
animal models (transgenic and toxin-induced) indicate that mitochondrial dysfunction and 
oxidative damage play a central role in the pathogenesis of a number of common 
neurodegenerative diseases, including Parkinson’s, Alzheimer’s, and Huntington’s Disease. 
There is ample evidence showing that impairment of different MRC complexes was found in 
various neurodegenerative diseases. The main purpose of this study was to provide additional 
mechanistic insights for the role of COX and mitochondria in neural cell viability under two 
different toxic conditions. A treatment of neural cells with NPA and 6-OHDA was selected as 
an in vitro model for HD and PD, respectively (Pang & Geddes, 1997; Lotharius et al., 1999).  
In first section I would like to discuss the effect of NPA toxicity on astrocytes derived from 
tree different brain regions. The administration of NPA yielded in an intense expression of 
COX IV-2 isoform associated with  increased ROS production and necrotic cell death. The 
highest COX IV-2/COXIV-1 ratio and cell death was found in astrocytes from striatum. 
Additionally, application of siRNA against COX IV-2 signifficantly reversed NPA mediated 
toxic effects. In the second part I will try to explain the functional importance of the elevated 
expression of COX isoform IV-2 upon NPA toxicity in primary astrocytic cultures. Finaly, in 
the last section I would like to discuss the influence of 6-OHDA on mitochondrial genes 
expression, ATP and ROS production, morphology and survival of primary mesencephalic 
neurons in a gender-specific manner. 
 
Proper function and survival of CNS depends on bidirectional neuron–astrocyte 
interactions. Increasing evidence shows that astrocytes have a critical role in maintenance of 
the neuronal microenvironment and in the continuous supply of fuel for oxidative neuronal 
metabolism. The respiratory capabilities of astrocytes can be up- or down-regulated by 
signaling metabolic control mechanisms (Hertz et al., 2007). In the absence of astrocytes, 
neurons are more prone to the effects of mitochondrial toxins and excitotoxic damage (Dugan 
et al., 1995; Singh et al., submitted). The potential role of mitochondria function from 
astrocyte during NPA-mediated toxicity has been examined. Characteristically for HD is cell 
death which predominantly occurs in the striatal GABAergic neurones and deep layers of the 
cerebral cortex (Ferrante et al.,1987; de la Monte et al., 1988; Martin and Gusella, 1986). 
Intoxication with NPA produce prominent striatal degeneration in rats and non-human 
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primates followed by cell loss in certain areas of the cerebral cortex anatomically connected 
to the striatum (Brouillet et al., 1995; Beal, 2000; Blum et al., 2001; Mittoux et al., 2002).  
The in vitro study of NPA applied to astrocytes supports the concept of a selectively higher 
vulnerability of the striatum in HD. Striatal astrocytes showed a higher vurnerability when 
compared with cortical and mesencephalic cells. Oxidative damage and metabolic dysfunction 
have been implicated in HD (Browne et al., 1997). The peroxide levels in striatal astrocytes 
exceeded those in cortical and mesencephalic cells by several fold. NPA as an inhibitor of 
SDH, complex II of the MRC, impairs mitochondrial energy production (Ayla et al., 2007; 
Beal et al., 2005; Gu et al., 1996; Schapira, 1997). Surprisingly increased instead of the 
expected decreased intracellular ATP levels were detected. These levels were highest in 
cortical and lowest in striatal astrocytes. A maintained oxidative energy production by the 
respiratory chain during complex II inhibition could, at least in part, be explained by electron 
entry via complex I of the MRC.  
Moreover, astrocytes in the conditions of greater energy demands are releasing a metabolic 
intermediate, lactic acid (Pellerin & Magistretti, 2003; 2004). Supportively, Dringen and 
collegues (Dringen et al., 1993; Wiesinger et.al., 1997) considered glycogen in astrocytes as a 
store for generating lactic acid rather than glucose. Although our experiments indicate that 
glycogen content was only marginally decreased in NPA-treated astrocytes, this change could 
point at glycogen as a source for anaerobic ATP generation additionally to the utilization of 
exogenous glucose provided in the cell culture medium.  
 
Generally elevated cell death rates were rather caused by necrosis than apoptosis. 
Furtheremore, ROS levels were highest in striatal and lowest in cortical astrocytes. With 
respect to elevated ATP levels, ROS increase seems to be the major reason for NPA-mediated 
cell death. Cell death rates revealed subtle differences between the three brain regions. The 
smallest increase in ATP level and the highest peroxide production in striatal astrocytes can 
explaine intense necrosis among cultured cells from this brain region when compared with 
cortex or mesencephalon. Increased rates of necrosis were accompanied by increased COX 
IV-2 and decreased COX IV-1 protein levels. Changes in protein expression were preceded 
by an up-regulation of cox4i2 and down-regulation of cox4i1 transcript levels, specifically in 
striatal astrocytes. Under normal culturing conditions COX IV-1 is the predominant isoform 
in astrocytes. Cortical and mesencephalic cells exhibited much lower COX IV-2/COX IV-1 
ratio due to up-regulated or constant COX IV-1 additionally to increased COX IV-2 levels, 
respectively. This could be the reason for a partial protection of astrocytes from those brain 
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regions. A COX IV-2 specific knock-down by applying siRNA caused a decrease of necrotic 
cell death rates in all three brain regions indicating a relationship between COX subunit IV 
isoform expression pattern and mitochondrial peroxide production and necrotic cell death. A 
similar switch between cox4i1 and cox4i2 transcripts has been observed under hypoxic 
conditions. Moreover, ATP regulation was correlated with COX activity (Horvat et al., 2006). 
COX is the rate-limiting enzyme of respiratory chain and this enzyme has the lowest 
excess capacity (Villani et al., 1997). COX is known to be regulated by allosteric factors, such 
as ATP/ADP binding to the N-terminus of COX subunit VI-1. This enables the enzyme to 
detect ATP level and adjust COX and MRC activity to energy demand (Arnold & Kadenbach, 
1997; Horvat et al., 2006; Singh et al., 2009). Interestingly our study on astrocytes under 
hypoxic or toxic conditions indicates that a switch from cox4i1 to cox4i2 is accompanied by 
increased catalytic activity of COX at the expense of an abolished sensitivity of the enzyme 
towards the cellular energy level (Horvat et al., 2006; Singh et al., 2009). This, in turn, could 
serve as an additional explanation of increased intracellular ATP in NPA mediated toxicity. 
  
With respect to our in vitro data on the role of COX in NPA-mediated toxicity and 
numerous reports about mitochondrial pathology being correlated to neurodegenerative 
diseases I aimed to examine the possible role of this terminal enzyme in an in vitro model of 
PD. It is well-accepted that PD shows gender dependence with a higher incidence in males 
than in females. This indicates that the mitochondria of neuronal cells may also exhibit sexual 
dependence with respect to structural and functional characteristics of these organelles during 
toxic and degenerative processes. Therefore, I applied 6-OHDA, a mitochondrial toxin 
commonly used as an in vitro model for PD (Lotharius et al., 1999), on cultivated 
mesencephalic neurons derived from female and male embryonic brains. In agreement with a 
number of in vitro and in vivo studies (Lotharius et al., 1999; Perier et al., 2005) I detected a 
predominance of apoptotic cell death in 6-OHDA treated mesencephalic neurons. 
Additionally, the applied viability assays revealed a higher vulnerability of male compared 
with female mesencephalic neurons. According to previous reports, inhibition of complex I 
generates burst of ROS (Ramsay & Singer, 1992; Lotharius et al., 1999). This is consistent 
with my results. During 6-OHDA toxicity increased ROS production, impaired oxidative 
phosphorylation, alterations in membrane permeability, decline mitochondrial membrane 
potential, calcium influx, loss of ATP and, finally, excitotoxic cell death processes were 
observed (White & Reynolds, 1996). Surprisingly, my data reveal that increased ROS 
production and apoptosis is not accompanied by a diminished ATP level. The blockade of 
 94 
complex I was followed by decreased transcript levels of representative mitochondria-
encoded, catalytic subunits of the respiratory chain complexes I, III and V which could 
additionally lead to decreased respiratory chain activity (Huerta et al., 2005; Extrand et al., 
2007). Although the mitochondrial transcription level is decreased, protein levels are 
apparently preserved for the duration of 6-OHDA treatment (Saikumar & Ramakrishna 
Kurup, 1985). Furthermore, COX as a rate-limiting enzyme of respiratory chain has the 
lowest excess capacity (Villani et al., 1998), thus a down-regulation of COX subunits should 
evoke an immediate effect on MRC activity. However, the transcription of neither the 
mitochondria-encoded cox2 nor the nucleus-encoded cox4i1 was significantly decreased 
under 6-OHDA conditions, which allows guaranteed optimal COX activity. In addition, 
another isoform of COX subunit IV, COX IV-2 was expressed in neurons to meet their energy 
demands. Treatment with 6-OHDA caused a decrease of cox4i2 transcription and COX IV-2 
protein levels, whereas cox4i1 transcription and COX IV-1 protein expression remained 
unchanged, thereby constraining maximal COX activity.  
This study indicates that the underlying mechanism of a higher vulnerability of male vs. 
female neurons could be due to higher ROS levels and more pronounced down-regulation of 
mitochondrial gene transcription, especially the subunit ND1 (Marella et al., 2008) and ATP6 
of complex I and V, respectively. This in turn could account for a more diminished respiratory 
chain activity and subsequently lower ATP levels in the male compared with female cells.  
The sex difference in Parkinson’s disease, with a higher susceptibility in men, suggests a 
modulatory effect of sex steroids in the brain. Estrogen and other steroid hormones such as 
progesterone, testosterone, and glucocorticoids as well as other members of the 
hypothalamic–pituitary–gonadal axis have been shown to act protective on neuronal survival 
during neurodegenerative, neurotoxic, and neuroinflammatory processes and might improve 
cognitive performance under pathological and normal physiological conditions (Dulzen & 
McDermott, 2000; Webber et al. 2005; Pozzi et al. 2006; Schumacher et al. 2007). Both 
genomic and non-genomic actions of estrogen converge to promote survival factors and show 
sex differences. Neuroprotection by estrogen involves activation of signaling molecules such 
as the phosphatidylinositol-3 kinase/Akt and the mitogen-activated protein kinase pathways 
(D’Astous et al., 2006). Interaction with growth factors, such as insulin-like growth factor 1, 
also contributes to protective actions of estrogen (Cardona-Gómez et al., 2001). Additionally, 
in in vitro and in vivo models of PD, estrogen protects dopaminergic cells from toxic 
compounds, such as 6-OHDA (Dluzen, 1997) and MPP+ (Bains et al., 2007). Here, I show 
that E counteracts 6-OHDA-induced increase of ROS levels thereby decreasing cell death 
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rates of mesencephalic neurons from both gender. In the literature, there are several reports 
suggesting mitochondria as a putative and promising target for estrogen-mediated cell 
protection (Araujo et al. 2008; Arnold et al. 2008; Brinton, 2008; Klinge, 2008; Simpkins & 
Dykens 2008). Estrogen is considered to be neurotrophic for dopaminergic neurons of the 
nigrostriatal system (Reisert et al., 1987; Beyer & Karolczak, 2000; Ivanova & Beyer, 2003) 
and affects the expression of mitochondrial proteins by regulating the transcription of 
mitochondrial and nuclear genes which are followed by increased respiratory chain activity 
and protection of cells from oxidative stress and cell death.  
This study clearly manifest that COX subunit IV isoforms play an essential and specific 
role for mitochondrial energy metabolism, oxidative stress, and consequently survival of 
neural cells under different toxic conditions.   
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9 Summary 
Mitochondria play a crucial role in neurodegenerative diseases. Different respiratory 
chain defects have been identified for Parkinson's disease (PD: complex I), Huntington's 
disease (HD: complex II) or Alzheimer’s disease (AD: complex IV). Additionally, studies 
with toxins that mimic neurodegenerative disorders when applied in vivo clearly support the 
pivotal role of mitochondrial enzyme complexes in neurodegeneration.  
Thus, I examined the effects of two structurally unrelated mitochondrial toxins on 
mitochondrial regulation, function and cell survival: 6-hydroxydopamine (6-OHDA) which 
impairs NADH dehydrogenase (ND; complex I) and 3-nitropropionic acid (NPA) which 
inhibits succinate dehydrogenase (SDH; complex II). Data shown here indicate that the 
terminal enzyme of respiratory chain, cytochrome c oxidase (COX), is also involved in the in 
vitro effects exerted by these two neurotoxins. 
With respect to the potential role of COX in toxin-induced neural cell death, I found that 
COX subunit IV isoforms play an essential brain region-specific role for mitochondrial 
energy metabolism, oxidative stress, and consequently survival of astrocytes under toxic 
conditions. NPA-treated astrocytes from striatum showed a higher vulnerability than those 
from cortex and mesencephalon. The lowest ATP level together with the highest reactive 
oxygen species (ROS) production in striatal astrocytes could explain the highest level of 
necrotic cell death rates in astrocyte cultures from striatum. The changes in ATP and ROS 
levels were caused by increased COX IV-2/COX IV-1 ratio due to up-regulated COX isoform 
IV-2 and down-regulated COX isoform IV-1 expression which is most pronounced in striatal 
astrocytes. Thus, COX plays a brain region-specific role in cell viability under toxic 
conditions. The underlying mechanism of this regulatory process involves the binding of ATP 
to COX subunit VI-1 in the presence of a high ATP/ADP ratio, thereby causing an allosteric 
inhibition of COX. This mechanism is abolished by the expression of COX isoform IV-2 
(Singh et al., 2009). Overall, my in vitro observations support the concept of a selective 
vulnerability of striatal astrocytes in HD, which is, at least in part, based on increased COX 
IV-2 transcription accompanied by elevated ROS levels and increased necrosis rates.  
In the second part, I analyzed the possible role of nucleus-encoded COX subunit IV 
isoforms and mitochondria-encoded catalytic subunits of MRC complexes for the  survival of 
mesencephalic female and male neurons during 6-OHDA intoxication. I found that female 
neurons are protected better than male cells from apoptotic and necrotic cell death. This 
protection may be explained by a less severe down-regulation of catalytic subunits of complex 
 97
I and V accompanied by higher ATP level and lower ROS production in female when 
compared to male neurons. I show that estrogen (E) counteracts 6-OHDA-induced increase of 
ROS levels thereby decreasing cell death rates of mesencephalic neurons. 
The data presented herein support the hypothesis that mitochondrial toxins lead to 
increased ROS production through changes of MRC function, thereby contributing to 
mitochondrial toxin-induced cell death. Further exploration of the postulated regulatory role 
of COX subunit IV and its isoforms during pathological conditions can provide development 
of new therapeutical strategies that may target basic mitochondrial processes such as energy 
production and ROS generation. Numerous studies demonstrate the direct or indirect actions 
of mutated proteins which are present in neurodegenerative diseases such as mutated 
huntingtin (Htt) or α-synuclein on mitochondrial structure and function. Focus of future 
research on the influence of pathogenic proteins on MRC enzymes can provide additional 
information on the processes occurring during neurodegeneration. Therefore, we think, that 
based on our in vitro studies, the role of COX in the regulation of mitochondria during 
neurodegeneration should be verified in animal models with particular emphasis on brain 
region- and gender-specificity. 
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10 Zusammenfassung  
Mitochondrien spielen eine entscheidende Rolle bei neurodegenerativen Erkrankungen. 
Verschiedene Atmungskettenmängel sind für Morbus Parkinson (PD: Komplex I), Chorea 
Huntington (HD: Komplex II) oder der Alzheimer-Krankheit (AD: Komplex IV) identifiziert 
worden. Darüber hinaus unterstützen Studien mit in vivo angewendeten Toxinen, die 
neurodegenerative Erkrankungen imitieren, ,  die zentrale Rolle der mitochondrialen 
Enzymkomplexe.  
So untersuchte ich die Effekte von zwei strukturell unabhängigen mitochondrialen Toxinen 
auf die mitochondriale  Regulation, Funktion und das Überleben von Zellen: 6-
Hydroxydopamin (6-OHDA), dass die NADH-Dehydrogenase (ND; Komplex I) 
beeinträchtigt und 3-Nitropropionsäure (NPA), welches die Succinat-Dehydrogenase (SDH; 
Komplex II) hemmt. Die Ergebnisse  hier zeigen, dass das terminale Enzym der 
Atmungskette, Cytochrom c Oxidase (COX), auch  an den in-vitro-Effekten  dieser  
Neurotoxine  beteiligt ist. 
In Bezug auf die potenzielle Rolle der COX bei Toxin-induziertem neuronalen Zelltod, 
fand ich, dass Isoformen der COX Untereinheit IV  eine wichtige Hirnregion-spezifische 
Rolle für den mitochondrialen Energiestoffwechsel, oxidativen Stress und damit das 
Überleben von Astrozyten unter toxischen Bedingungen spielen. NPA-behandelten 
Astrozyten aus dem Striatum zeigten eine höhere Anfälligkeit als die aus Kortex und 
Mittelhirn .  Den niedrigsten ATP-Spiegel zusammen mit der höchsten reaktiven 
Sauerstoffspezies- (ROS-) Produktion in striatalen Astrozyten die hohe nekrotische 
Zelltodrate in Astrozytenkulturen des Striatums  erklären. Die Veränderungen von ATP- und 
ROS-Niveau  wurden durch ein erhöhtes COX IV-2/COX IV-1-Verhältnis durch hoch-
regulierte COX Isoform IV-2 und herunter-regulierte COX Isoform IV-1-Expression 
verursacht, welche  am stärksten  in striatalen Astrozyten ausgeprägt ist. So spielt die COX 
eine Hirnregion-spezifische Rolle für die  Lebensfähigkeit der Zellen unter toxischen 
Bedingungen. Der zugrunde liegende Mechanismus dieses regulatorischen Prozesses 
beinhaltet die Bindung von ATP an die COX Untereinheit VI-1 in Gegenwart eines hohen 
ATP/ADP-Verhältnisses, die die  allosterische Hemmung  der COX verursacht. Dieser 
Mechanismus wird durch die Expression der COX Isoform IV-2 unterbunden (Singh et al , 
2009). 
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Insgesamt unterstützen meine in vitro Beobachtungen das Konzept einer selektiven 
Anfälligkeit der striatalen Astrozyten in HD, die, zumindest teilweise, auf einer erhöhten 
COX IV-2 Transkription  und erhöhter ROS-Produktion und  Nekroserate beruht .  
Im zweiten Teil meiner Arbeit, analysierte ich die mögliche Rolle von Kern-kodierten 
COX Untereinheit IV Isoformen und Mitochondrien-kodierten repräsentativen katalytischen 
Untereinheiten der mitochondrialen Atmungsketten (MRC)-Komplexe für das Überleben der 
weiblichen und männlichen mesencephalischen Neuronen während der 6-OHDA Applikation. 
Ich fand, dass weibliche Neurone besser als männliche Zellen vor apoptotischem und 
nekrotischem Zelltod geschützt sind. Dieser Schutz könnte durch eine weniger starke 
Herunter-Regulation der katalytischen Untereinheiten des Komplexes I und V und eine 
höhere ATP- und niedrigere ROS-Produktion in weiblichen verglichen mit männlichen 
Neuronen erklärt werden . Ich zeige, dass Östrogen (E) einem 6-OHDA-induzierten ROS-
Anstieg  und dadurch verringerter Zelltodrate von mesencephalischen Neuronen 
entgegenwirkt. 
Die hier präsentierten Daten unterstützen die Hypothese,  dass mitochondriale Toxine zu 
einer erhöhten ROS-Produktion durch Veränderungen der MRC-Funktion und damit zu 
mitochondrialem Toxin-induzierten Zelltod führen. Die weitere Erforschung der  
regulatorischen Rolle der COX Untereinheit IV und ihrer Isoformen unter pathologischen 
Bedingungen kann bei der  Entwicklung neuer therapeutischer Strategien, die die 
grundlegenden Prozesse wie die mitochondriale Energie-und ROS- Produktion adressieren, 
von Niutzen sein. Zahlreiche Studien belegen die direkte oder indirekte Wirkung von  
mutierten Proteinen, die bei neurodegenerativen Erkrankungen vorhanden sind, wie z. B. 
mutiertes Huntingtin (Htt) oder α-Synuclein, auf die mitochondriale Struktur und Funktion. 
Schwerpunkte der künftigen Forschung über den Einfluss von pathogenen Proteinen auf MRC 
Enzyme können zusätzliche Informationen über die Vorgänge während  neurodegenerativer 
Porzesse liefern. Deshalb denken wir, dass basierend auf unseren in-vitro-Studien, die Rolle 
der COX für der Regulation der Mitochondrien bei Neurodegeneration  in Tiermodellen mit 
besonderem Schwerpunkt auf Hirnregion-und geschlechtsspezifischen Besonderheiten 
überprüft werden sollte. 
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